

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2014 April 15; 6(4): 83-103



## Editorial Board

2011-2015

The *World Journal of Gastrointestinal Oncology* Editorial Board consists of 428 members, representing a team of worldwide experts in gastrointestinal oncology. They are from 40 countries, including Argentina (2), Australia (10), Belgium (5), Brazil (2), Canada (4), Chile (2), China (56), Czech Republic (1), Denmark (1), Finland (3), France (7), Germany (24), Greece (13), Hungary (2), India (9), Iran (2), Ireland (2), Israel (4), Italy (41), Japan (47), Kuwait (2), Mexico (1), Netherlands (7), New Zealand (2), Norway (1), Poland (3), Portugal (5), Romania (1), Saudi Arabia (1), Serbia (2), Singapore (4), South Korea (27), Spain (10), Sweden (5), Switzerland (2), Syria (1), Thailand (1), Turkey (6), United Kingdom (15), and United States (95).

### EDITORS-IN-CHIEF

Wasaburo Koizumi, *Kanagawa*  
Hsin-Chen Lee, *Taipei*  
Dimitrios H Roukos, *Ioannina*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Jian-Yuan Chai, *Long Beach*  
Antonio Macrì, *Messina*  
Markus Kurt Menges, *Schwaebisch Hall*

### GUEST EDITORIAL BOARD MEMBERS

Da-Tian Bau, *Taichung*  
Jui-I Chao, *Hsinchu*  
Chiao-Yun Chen, *Kaohsiung*  
Joanne Jeou-Yuan Chen, *Taipei*  
Shih-Hwa Chiou, *Taipei*  
Tzeon-Jye Chiou, *Taipei*  
Jing-Gung Chung, *Taichung*  
Yih-Gang Goan, *Kaohsiung*  
Li-Sung Hsu, *Taichung*  
Tsann-Long Hwang, *Taipei*  
Long-Bin Jeng, *Taichung*  
Kwang-Huei Lin, *Taoyuan*  
Joseph T Tseng, *Tainan*  
Jaw Yuan Wang, *Kaohsiung*  
Tzu-Chen Yen, *Taoyuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

María Eugenia Pasqualini, *Córdoba*  
Lydia Inés Puricelli, *Buenos Aires*



#### Australia

Ned Abraham, *NSW*

Stephen John Clarke, *NSW*  
Michael Gnant, *Vienna*  
Michael McGuckin, *South Brisbane*  
Muhammed Ashraf Memon, *Queensland*  
Liang Qiao, *NSW*  
Rodney John Scott, *NSW*  
Joanne Patricia Young, *Herston Q*  
Xue-Qin Yu, *NSW*  
Xu Dong Zhang, *NSW*



#### Belgium

Wim Peter Ceelen, *Ghent*  
Van Cutsem Eric, *Leuven*  
Suriano Gianpaolo, *Brussels*  
Xavier Sagaert, *Leuven*  
Jan B Vermorken, *Edegem*



#### Brazil

Raul Angelo Balbinotti, *Caxias do Sul*  
Sonia Maria Oliani, *Colombo*



#### Canada

Alan Graham Casson, *Saskatoon*  
Hans Tse-Kan Chung, *Toronto*  
Rami Kotb, *Sherbrooke*  
Sai Yi Pan, *Ottawa*



#### Chile

Alejandro Hernan Corvalan, *Santiago*  
Juan Carlos Roa, *Temuco*



#### China

Dong Chang, *Beijing*  
George G Chen, *Hong Kong*  
Yong-Chang Chen, *Zhenjiang*  
Chi-Hin Cho, *Hong Kong*  
Ming-Xu Da, *Lanzhou*  
Xiang-Wu Ding, *Xiangfan*  
Yan-Qing Ding, *Guangzhou*  
Bi Feng, *Chengdu*  
Jin Gu, *Beijing*  
Qin-Long Gu, *Shanghai*  
Hai-Tao Guan, *Xi'an*  
Chun-Yi Hao, *Beijing*  
Yu-Tong He, *Shijiazhuang*  
Jian-Kun Hu, *Chengdu*  
Huang-Xian Ju, *Nanjing*  
Wai-Lun Law, *Hong Kong*  
Ming-Yu Li, *Lanzhou*  
Shao Li, *Beijing*  
Ka-Ho Lok, *Hong Kong*  
Maria Li Lung, *Hong Kong*  
Simon Ng, *Hong Kong*  
Wei-Hao Sun, *Nanjing*  
Qian Tao, *Hong Kong*  
Bin Wang, *Nanjing*  
Chun-You Wang, *Wuhan*  
Kai-Juan Wang, *Zhengzhou*  
Wei-Hong Wang, *Beijing*  
Ya-Ping Wang, *Nanjing*  
Ai-Wen Wu, *Beijing*  
Zhao-Lin Xia, *Shanghai*  
Xue-Yuan Xiao, *Beijing*  
Dong Xie, *Shanghai*  
Guo-Qiang Xu, *Hangzhou*  
Yi-Zhuang Xu, *Beijing*  
Winnie Yeo, *Hong Kong*  
Ying-Yan Yu, *Shanghai*

Siu Tsan Yuen, *Hong Kong*  
Wei-Hui Zhang, *Harbin*  
Li Zhou, *Beijing*  
Yong-Ning Zhou, *Lanzhou*



### Czech Republic

Ondrej Slaby, *Brno*



### Denmark

Hans Jørgen Nielsen, *Hvidovre*



### Finland

Riyad Bendardaf, *Turku*  
Pentti Ilmari Sipponen, *Espoo*  
Markku Voutilainen, *Jyväskylä*



### France

Bouvier Anne-Marie, *Cedex*  
Stéphane Benoist, *Boulogne*  
Ouaissi Mehdi, *Marseille*  
Jean-François Rey, *Jean-François Rey*  
Karem Slim, *Clermont-Ferrand*  
David Tougeron, *Poitiers*  
Isabelle Van Seuning, *Lille*



### Germany

Hajri Amor, *Freiburg*  
Han-Xiang An, *Marburg*  
Karl-Friedrich Becker, *München*  
Stefan Boeck, *Munich*  
Dietrich Doll, *Marburg*  
Joachim Drevs, *Freiburg*  
Volker Ellenrieder, *Marburg*  
Ines Gütgemann, *Bonn*  
Jakob Robert Izbicki, *Hamburg*  
Gisela Keller, *München*  
Jörg H Kleeff, *Munich*  
Axel Kleespies, *Munich*  
Hans-Joachim Meyer, *Solingen*  
Lars Mueller, *Kiel*  
Martina Müller-Schilling, *Heidelberg*  
Joachim Pfannschmidt, *Heidelberg*  
Marc André Reymond, *Bielefeld*  
Robert Rosenberg, *München*  
Ralph Schneider, *Marburg*  
Helmut K Seitz, *Heidelberg*  
Nikolas Hendrik Stoecklein, *Düsseldorf*  
Oliver Stoeltzing, *Mainz*  
Ludwig G Strauss, *Heidelberg*



### Greece

Ekaterini Chatzaki, *Alexandroupolis*  
Eelco de Bree, *Heraklion*  
Maria Gazouli, *Athens*  
Vassilis Georgoulas, *Heraklion*  
John Griniatsos, *Athens*  
Ioannis D Kanellos, *Thessaloniki*  
Vaios Karanikas, *Larissa*  
Georgios Koukourakis, *Athens*

Michael I Koukourakis, *Alexandroupolis*  
Gregory Kouraklis, *Athens*  
Kostas Syrigos, *Athens*  
Ioannis A Voutsadakis, *Larissa*



### Hungary

László Herszényi, *Budapest*  
Zsuzsa Schaff, *Budapest*



### India

Uday Chand Ghoshal, *Lucknow*  
Ruchika Gupta, *New Delhi*  
Kalpesh Jani, *Vadodara*  
Ashwani Koul, *Chandigarh*  
Balraj Mittal, *Lucknow*  
Rama Devi Mittal, *Lucknow*  
Susanta Roychoudhury, *Kolkata*  
Yogeshwar Shukla, *Lucknow*  
Imtiaz Ahmed Wani, *Kashmir*



### Iran

Reza Malekzadeh, *Tehran*  
Mohamad Amin Pourhoseingholi, *Tehran*



### Ireland

Aileen Maria Houston, *Cork*  
Colm Ó'Moráin, *Dublin*



### Israel

Nadir Arber, *Tel Aviv*  
Eytan Domany, *Rehovot*  
Dan David Hershko, *Haifa*  
Yaron Niv, *Patch Tikva*



### Italy

Massimo Aglietta, *Turin*  
Domenico Alvaro, *Rome*  
Azzariti Amalia, *Bari*  
Marco Braga, *Milan*  
Federico Cappuzzo, *Rozzano*  
Lorenzo Capussotti, *Torino*  
Fabio Carboni, *Rome*  
Vincenzo Cardinale, *Rome*  
Luigi Cavanna, *Piacenza*  
Massimo Colombo, *Milan*  
Valli De Re, *Pordenone*  
Ferdinando De Vita, *Naples*  
Riccardo Dolcetti, *Aviano*  
Pier Francesco Ferrucci, *Milano*  
Francesco Fiorica, *Ferrara*  
Gennaro Galizia, *Naples*  
Silvano Gallus, *Milano*  
Milena Gusella, *Trecenta*  
Carlo La Vecchia, *Milano*  
Roberto Francesco Labianca, *Bergamo*  
Massimo Libra, *Catania*  
Roberto Manfredi, *Bologna*  
Gabriele Masselli, *Viale del Policlinico*  
Simone Mocellin, *Padova*

Gianni Mura, *Arezzo*  
Gerardo Nardone, *Napoli*  
Gabiella Nesi, *Florence*  
Francesco Perri, *San Giovanni Rotondo*  
Francesco Recchia, *Avezzano*  
Vittorio Ricci, *Pavia*  
Fabrizio Romano, *Monza*  
Antonio Russo, *Palermo*  
Daniele Santini, *Rome*  
Claudio Sorio, *Verona*  
Cosimo Sperti, *Padova*  
Gianni Testino, *Genova*  
Giuseppe Tonini, *Rome*  
Bruno Vincenzi, *Rome*  
Zoli Wainer, *Forlì*  
Angelo Zullo, *Rome*



### Japan

Suminori Akiba, *Kagoshima*  
Keishiro Aoyagi, *Kurume*  
Narikazu Boku, *Shizuoka*  
Yataro Daigo, *Tokyo*  
Itaru Endo, *Yokohama*  
Mitsuhiro Fujishiro, *Tokyo*  
Osamu Handa, *Kyoto*  
Kenji Hibi, *Yokohama*  
Asahi Hishida, *Nagoya*  
Eiso Hiyama, *Hiroshima*  
Atsushi Imagawa, *Okayama*  
Johji Inazawa, *Tokyo*  
Terumi Kamisawa, *Tokyo*  
Tatsuo Kanda, *Niigata*  
Masaru Katoh, *Tokyo*  
Takayoshi Kiba, *Hyogo*  
Hajime Kubo, *Kyoto*  
Hiroki Kuniyasu, *Kashihara*  
Yukinori Kurokawa, *Osaka*  
Chihaya Maesawa, *Morioka*  
Yoshinori Marunaka, *Kyoto*  
Osam Mazda, *Kyoto*  
Shinichi Miyagawa, *Matsumoto*  
Eiji Miyoshi, *Suita*  
Toshiyuki Nakayama, *Nagasaki*  
Masahiko Nishiyama, *Saitama*  
Koji Oba, *Kyoto*  
Masayuki Ohtsuka, *Chiba*  
Masao Seto, *Aichi*  
Tomoyuki Shibata, *Aichi*  
Mitsugi Shimoda, *Tochigi*  
Haruhiko Sugimura, *Hamamatsu*  
Tomomitsu Tahara, *Aichi*  
Shinji Takai, *Osaka*  
Satoru Takayama, *Nagoya*  
Akio Tomoda, *Tokyo*  
Akihiko Tsuchida, *Tokyo*  
Yasuo Tsuchiya, *Niigata*  
Takuya Watanabe, *Niigata*  
Toshiaki Watanabe, *Tokyo*  
Yo-ichi Yamashita, *Hiroshima*  
Hiroki Yamaue, *Wakayama*  
Hiroshi Yasuda, *Kanagawa*  
Hiroshi Yokomizo, *Kumamoto*  
Yutaka Yonemura, *Osaka*  
Reigetsu Yoshikawa, *Hyogo*



### Kuwait

Fahd Al-Mulla, *Safat*

Salem Alshemmari, *Safat*



**Mexico**

Oscar G Arrieta Rodriguez, *Mexico City*



**Netherlands**

Jan Paul De Boer, *Amsterdam*  
Bloemena Elisabeth, *Bloemena Elisabeth*  
Peter JK Kuppen, *Leiden*  
Gerrit Albert Meijer, *Amsterdam*  
Anya N Milne, *Utrecht*  
Godefridus J Peters, *Amsterdam*  
Cornelis FM Sier, *Leiden*



**New Zealand**

Lynnette Robin Ferguson, *Auckland*  
Jonathan Barnes Koea, *Auckland*



**Norway**

Kjetil Søreide, *Stavanger*



**Poland**

Andrzej Szkaradkiewicz, *Poznan*  
Michal Tenderenda, *Polskiego*  
Jerzy Wydmański, *Gliwice*



**Portugal**

Maria de Fátima Moutinho Gärtner, *Porto*  
Celso Albuquerque Reis, *Porto*  
Lucio Lara Santos, *Porto*  
Maria Raquel Campos Seruca, *Porto*  
Manuel António Rodrigues Teixeira, *Porto*



**Romania**

Marius Raica, *Timisoara*



**Saudi Arabia**

Ragab Hani Donkol, *Abha*



**Serbia**

Milos M Bjelovic, *Belgrade*  
Goran Zoran Stanojevic, *Nis*



**Singapore**

Peh Yean Cheah, *Singapore*  
Si-Shen Feng, *Singapore*  
Zhi-Wei Huang, *Singapore*  
Qi Zeng, *Singapore*



**South Korea**

Seungmin Bang, *Seoul*  
Daeho Cho, *Seoul*  
Byung Ihn Choi, *Seoul*  
Hyun Cheol Chung, *Seoul*  
Sang-Uk Han, *Suwon*  
Jun-Hyeog Jang, *Incheon*  
Seong Woo Jeon, *Daegu*  
Dae Hwan Kang, *Mulgeum-Gigu*  
Gyeong Hoon Kang, *Seoul*  
Dong Yi Kim, *Gwangju*  
Jae J Kim, *Seoul*  
Jin Cheon Kim, *Seoul*  
Jong Gwang Kim, *Daegu*  
Min Chan Kim, *Busan*  
Samyong Kim, *Daejeon*  
Inchul Lee, *Seoul*  
Jung Weon Lee, *Seoul*  
Kyu Taek Lee, *Seoul*  
Kyung Hee Lee, *Daegu*  
Na Gyong Lee, *Seoul*  
Suk Kyeong Lee, *Seoul*  
Jong-Baeck Lim, *Seoul*  
Young Joo Min, *Ulsan*  
Sung-Soo Park, *Seoul*  
Young Kee Shin, *Seoul*  
Hee Jung Son, *Seoul*  
Si Young Song, *Seoul*



**Spain**

Manuel Benito, *Madrid*  
Ignacio Casal, *Madrid*  
Antoni Castells, *Barcelona*  
Jose JG Marin, *Salamanca*  
Joan Maurel, *Barcelona*  
Emma Folch Puy, *Barcelona*  
Jose Manuel Ramia, *Guadalajara*  
Margarita Sanchez-Beato, *Madrid*  
Laura Valle, *Barcelona*  
Jesus Vioque, *San Juan*



**Sweden**

Nils Albiin, *Stockholm*  
Samuel Lundin, *Göteborg*  
Haile Mahteme, *Uppsala*  
Richard Palmqvist, *Umea*  
Ning Xu, *Lund*



**Switzerland**

Paul M Schneider, *Zurich*  
Luigi Tornillo, *Basel*



**Syria**

Zuhir Alshehabi, *Lattakia*



**Thailand**

Sopit Wongkham, *Khon Kaen*



**Turkey**

Uğur Coşkun, *Ankara*  
Sukru Mehmet Erturk, *Istanbul*  
Vedat Goral, *Diyarbakir*  
Yavuz Selim Sari, *Istanbul*  
Mesut Tez, *Ankara*  
Murat H Yener, *Istanbul*



**United Kingdom**

Shrikant Anant, *Oklahoma City*  
Runjan Chetty, *Scotland*  
Chris Deans, *Edinburgh*  
Dipok Kumar Dhar, *London*  
Thomas Ronald Jeffry Evans, *Glasgow*  
Giuseppe Garcea, *Leicester*  
Oleg Gerasimenko, *Liverpool*  
Neena Kalia, *Birmingham*  
Anthony Maraveyas, *East Yorkshire*  
Andrew Maw, *North Wales*  
Kymberley Thorne, *Swansea*  
Chris Tselepis, *Birmingham*  
Nicholas Francis Scot Watson, *Nottingham*  
Ling-Sen Wong, *Coventry*  
Lu-Gang Yu, *Liverpool*



**United States**

Mohammad Reza Abbaszadegan, *Phoenix*  
Gianfranco Alpini, *Temple*  
Seung Joon Baek, *Knoxville*  
Jamie S Barkin, *Miami Beach*  
Carol Bernstein, *Arizona*  
Paolo Boffetta, *New York*  
Kimberly Maureen Brown, *Kansas City*  
De-Liang Cao, *Springfield*  
Weibiao Cao, *Providence*  
Chris N Conteas, *Los Angeles*  
Pelayo Correa, *Nashville*  
Joseph John Cullen, *JCP*  
James Campbell Cusack, *Boston*  
Ananya Das, *Scottsdale*  
Juan Dominguez-Bendala, *Miami*  
Wafik S El-Deiry, *Philadelphia*  
Laura Elnitski, *Rockville*  
Guy Douglas Eslick, *Boston*  
Thomas Joseph Fahey III, *New York*  
James W Freeman, *San Antonio*  
Bruce Joseph Giantonio, *Philadelphia*  
Ajay Goel, *Dallas*  
Karen Gould, *Omaha*  
Nagana Gowda A Gowda, *West Lafayette*  
Stephen Randolph Grobmyer, *Florida*  
Young S Hahn, *Charlottesville*  
John W Harmon, *Maryland*  
Paul J Higgins, *New York*  
Steven Norbit Hochwald, *Gainesville*  
Jason L Hornick, *Boston*  
Qin Huang, *Duarte*  
Su-Yun Huang, *Houston*  
Jamal A Ibdah, *Columbia*  
Yihong Jiang-Cao Kaufmann, *Little Rock*  
Temitope Olubunmilayo Keku, *Chapel Hill*  
Saeed Khan, *Silver Spring*  
Vijay Pranjivan Khatri, *Sacramento*

Peter Sean Kozuch, *New York*  
Sunil Krishnan, *Houston*  
Robert R Langley, *Houston*  
Feng-Zhi Li, *New York*  
Otto Schiueh-Tzang Lin, *Seattle*  
Ke-Bin Liu, *Augusta*  
Rui-Hai Liu, *Ithaca*  
Xiang-Dong Liu, *Wilmington*  
Deryk Thomas Loo, *South San Francisco*  
Andrew M Lowy, *La Jolla*  
Bo Lu, *Nashville*  
David M Lubman, *Ann Arbor*  
James David Luketich, *Pittsburgh*  
Ju-Hua Luo, *Morgantown*  
Henry T Lynch, *Omaha*  
Shelli R Mcalpine, *San Diego*  
Ellen Darcy McPhail, *Rochester*  
Anil Mishra, *Cincinnati*  
Priyabrata Mukherjee, *Rochester*

Steffan Todd Nawrocki, *San Antonio*  
Kevin Tri Nguyen, *Pittsburgh*  
Shuji Ogino, *Boston*  
Macaulay Onuigbo, *Eau Claire*  
Jong Park, *Tampa*  
Philip Agop Philip, *Detriot*  
Blase N Polite, *Chicago*  
James Andrew Radosevich, *Chicago*  
Jasti S Rao, *Peoria*  
Srinevas Kadumpalli Reddy, *Durham*  
Raffaniello Robert, *New York*  
Stephen H Safe, *College Station*  
Muhammad Wasif Saif, *New Haven*  
Prateek Sharma, *Kansas City*  
Eric Tatsuo Shinohara, *Philadelphia*  
Liviu Andrei Sicinski, *Nashville*  
William Small Jr, *Chicago*  
Sanjay K Srivastava, *Amarillo*  
Gloria H Su, *New York*

Sujha Subramanian, *Waltham*  
Mitsushige Sugimoto, *Texas*  
David W Townsend, *Knoxville*  
Asad Umar, *Rockville*  
Ji-Ping Wang, *Buffalo*  
Zheng-He Wang, *Cleveland*  
Michael J Wargovich, *Charleston*  
Neal W Wilkinson, *Iowa City*  
Siu-Fun Wong, *Pomona*  
Shen-Hong Wu, *New York*  
Jing-Wu Xie, *Indianapolis*  
Ke-Ping Xie, *Houston*  
Hao-Dong Xu, *Rochester*  
Xiao-Chun Xu, *Houston*  
Gary Y Yang, *New York*  
Wan-Cai Yang, *Chicago*  
Zeng-Quan Yang, *Detroit*  
Zuo-Feng Zhang, *South Los Angeles*  
Andrew X Zhu, *Boston*



# World Journal of Gastrointestinal Oncology

## Contents

Monthly Volume 6 Number 4 April 15, 2014

### REVIEW

83

Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer

*Ganepola GAP, Nizin J, Rutledge JR, Chang DH*

### BRIEF ARTICLE

98

Colorectal carcinoma in a Southern Mediterranean country: The Libyan scenario

*Bodalal Z, Bendardaf R*

## Contents

*World Journal of Gastrointestinal Oncology*  
Volume 6 Number 4 April 15, 2014

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Masahiko Nishiyama, MD, PhD, Translational Research Center, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan

### AIM AND SCOPE

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

### INDEXING/ ABSTRACTING

*World Journal of Gastrointestinal Oncology* is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

**FLYLEAF** I-IV Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Su-Qing Liu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xiu-Xia Song*

**NAME OF JOURNAL**  
*World Journal of Gastrointestinal Oncology*

**ISSN**  
ISSN 1948-5204 (online)

**LAUNCH DATE**  
October 15, 2009

**FREQUENCY**  
Monthly

**EDITORS-IN-CHIEF**  
**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Person-

alized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Gastrointestinal Oncology*  
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road, Wanchai, Hong Kong, China  
Fax: +852-6557188  
Telephone: +852-31779906  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

**PUBLICATION DATE**  
April 15, 2014

**COPYRIGHT**  
© 2014 Baishideng Publishing Group Co., Limited. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>

## Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer

Ganepola AP Ganepola, Joel Nizin, John R Rutledge, David H Chang

Ganepola AP Ganepola, Joel Nizin, John R Rutledge, David H Chang, Center for Cancer Research and Genomic Medicine, The Daniel and Gloria Blumenthal Cancer Center, Paramus, NJ 07652, United States

Ganepola AP Ganepola, Joel Nizin, Department of Surgery, The Valley Hospital, Ridgewood, NJ 07450, United States

Author contributions: All the authors wrote the manuscript.

Supported by The Valley Hospital Foundation Research Fund; The community of The Valley Hospital in Ridgewood, NJ, especially Ms. Audrey Meyers, CEO, Mr. Anastasios Kozaitis, president of the Valley Hospital Foundation

Correspondence to: David H Chang, PhD, Research Scientist, Center for Cancer Research and Genomic Medicine, The Daniel and Gloria Blumenthal Cancer Center, The Valley Hospital, 1 Valley Health Plaza, Paramus, NJ 07652, United States. [davidhc9@gmail.com](mailto:davidhc9@gmail.com)

Telephone: +1-201-6345542 Fax: +1-201-6345383

Received: November 5, 2013 Revised: March 8, 2014

Accepted: March 17, 2014

Published online: April 15, 2014

### Abstract

Early screening for colorectal cancer (CRC) holds the key to combat and control the increasing global burden of CRC morbidity and mortality. However, the current available screening modalities are severely inadequate because of their high cost and cumbersome preparatory procedures that ultimately lead to a low participation rate. People simply do not like to have colonoscopies. It would be ideal, therefore, to develop an alternative modality based on blood biomarkers as the first line screening test. This will allow for the differentiation of the general population from high risk individuals. Colonoscopy would then become the secondary test, to further screen the high risk segment of the population. This will encourage participation and therefore help to reach the goal of early detection and thereby reduce the anticipated increasing global CRC incidence rate. A blood-based screening test is an

appealing alternative as it is non-invasive and poses minimal risk to patients. It is easy to perform, can be repeated at shorter intervals, and therefore would likely lead to a much higher participation rate. This review surveys various blood-based test strategies currently under investigation, discusses the potency of what is available, and assesses how new technology may contribute to future test design.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Colorectal neoplasms; Early detection of cancer; Colonoscopy; Biological markers; Blood; Messenger RNA; MicroRNA; Long non-coding RNA; DNA methylation; Microsatellite instability; Loss of heterozygosity; High-throughput nucleotide sequencing; Mass spectrometry; Real-time polymerase chain reaction; Microarray analysis

**Core tip:** Current colorectal cancer screening modalities are severely inadequate for global application because of high costs and a low participation rate. The alternative is to develop a blood-based screening test based on biomarkers which can replace colonoscopy as a first-line screening tool. The blood-based test should identify the high risk population, which will then be followed by colonoscopy as a secondary test. This review surveys the various experimental approaches and latest research into ideal biomarkers for the initial screening test, the pros and cons of each method and their potential to lead to a future screening test.

Ganepola GAP, Nizin J, Rutledge JR, Chang DH. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. *World J Gastrointest Oncol* 2014; 6(4): 83-97 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v6/i4/83.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v6.i4.83>

## INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer and fourth most common cause of cancer death in the world<sup>[1]</sup>. It is anticipated that as global communities become more developed and the world population ages, the morbidity and mortality rates due to CRC will increase substantially<sup>[2]</sup>. Although a number of early detection screening modalities have been used extensively in developed nations to lower the incidence and mortality rate, their overall high cost and low participation rate render them to be ineffective in controlling CRC on the global scale. Therefore, an alternative first line screening modality that has high sensitivity, high specificity, is relatively inexpensive and easily implemented, is urgently needed to help reduce the expected increase in global CRC burden. The main purpose of this review is to investigate the potential application of blood-based biomarkers in early diagnosis and surveillance of CRC cases.

## URGENT NEED FOR A NEW CRC SCREENING MODALITY

Cancer is the leading cause of death in countries with a very high human development index and is poised to become a major cause of morbidity and mortality in every region of the world in the next few decades<sup>[3]</sup>. The United Nations has forecasted that the global population will reach 7.2 billion by July 2013, but population growth will slow in the next few decades, reaching 9.6 billion in 2050 and 10.9 billion in 2100 according to the medium-variant projection<sup>[4]</sup>. The United Nations report further delineated that the population growth will trend toward a balance between declining fertility rate and increasing population longevity. The increase in the aged population is expected to translate into an increasing global burden of cancer incidence<sup>[3,5]</sup>. In particular, it is anticipated that when the global population as a whole becomes more developed through rapid societal and economic changes, infection-related cancers (*i.e.*, cervical, stomach and liver cancers) will continue to decline but will be replaced with an increasing number of cancers associated with reproductive, dietary, and hormonal factors (*i.e.*, breast, colorectal, lung, and prostate cancers) as is typically found in high human development index regions.

Therefore, it is crucial to develop an early diagnostic modality for CRC that can be adaptable, economical, and implemented en masse by the global community.

### Current screening options and their pros and cons

In the United States, CRC is the third most common cancer diagnosed among men and women and the second leading cause of cancer death with the estimation of 142280 new cases and 50830 deaths in 2013<sup>[6]</sup>. The five-year survival rate is 90% for cancer found localized or confined to the bowel wall, 70% for cancer with lymph node involvement, and 10% for cancer that has metastasized.

Clearly, these numbers demonstrate that screening and early detection would lead to better survival, prognosis, treatment options, and hence quality of life. In 1980, the American Cancer Society (ACS) issued a formal guideline for CRC screening in average-risk adults, including an annual digital rectal exam and stool guaiac slide test in addition to the performance of a sigmoidoscopy every three to five years<sup>[7]</sup>. Since the guideline was issued, the cancer morbidity and mortality rates, which peaked around 1985 in the United States, have been in steady decline<sup>[6]</sup>. It is conceivable that the decline of CRC rates is at least partially attributable to the implementation of early screening and surveillance programs<sup>[8]</sup>.

As of 2008, the basic screening modalities remain remarkably similar to those used in 1980 when the original guideline was issued, even when taking into account the development of newer technology in subsequent years<sup>[8]</sup>. In general, ACS, American College of Radiology (ACR), and the United States Preventive Services Task Force (USPSTF)<sup>[9]</sup> all agree on and emphasize the importance of CRC screening<sup>[8,10-12]</sup>. The recommended CRC screening modalities can be roughly divided into two different categories: fecal tests and direct structural exams.

The fecal tests are essentially “blood in the stool” tests. They can be performed using either a hemoglobin test [the guaiac-based Fecal Occult Blood Test (gFOBT)] or a newer and more sensitive version of an antibody-based globin test, known as the immunochemical FOBT or Fecal Immunochemical Test (FIT)<sup>[13]</sup>. In general, the gFOBT test is a non-invasive, inexpensive and easily applicable screening test which patients can readily perform in the comfort of their own home. Specimens from a FIT must be submitted to a laboratory for testing. The fecal tests help to reduce the risk of CRC death but has no effect on all-cause mortality<sup>[14]</sup>. They are not specific tests for CRC markers, and if found positive, the presence of CRC must still be confirmed by a direct structural exam such as colonoscopy or imaging procedures<sup>[15]</sup>. The fecal tests have high false positive rate for detecting CRC as gastrointestinal bleeding may occur in other conditions like colitis and hemorrhoids<sup>[16-18]</sup>. This, therefore, increases the burden of unnecessary colonoscopies and anxiety among patients<sup>[19]</sup>. It also may not detect precancerous lesions or early stage adenomas as bleeding may not be readily detectable in the presence of these conditions<sup>[20,21]</sup>. Regarding the fecal tests in general, the opportunity for CRC prevention is both limited and incidental and they are therefore not recommended as the solo screening test for CRC<sup>[8]</sup>.

Direct structural exams include endoscopic procedures, such as flexible sigmoidoscopy and colonoscopy, and imaging procedures, such as double-contrast barium enema and computed tomographic colonography. In general, both flexible sigmoidoscopy and colonoscopy are invasive procedures using a colonoscope. Sigmoidoscopy is a small-scale colonoscopy which can be performed with a simple preparation without sedation, and

is used to examine the lower half of the colon lumen as opposed to the entire colon. The complete colonoscopy allows direct mucosal inspection of the entire colon from the appendiceal orifice to the dentate line. Same-session biopsy sampling or definitive treatment by polypectomy in the case of precancerous polyps and some early-stage cancers can also be performed. The double-contrast barium enema and computed tomographic colonography are both imaging examinations of the colon in its entirety and are either noninvasive or minimally invasive. However, although they allow for complete examination of the colon, there is no opportunity for biopsy or polypectomy and must therefore be followed up by therapeutic colonoscopy when polyps are found.

### **Inadequacy of colonoscopy**

In the United States, colonoscopy has become the gold standard of CRC screening. It is one of the critical screening procedures recommended by ACS, ACR, and USPSTF, and it is also recommended by the American College of Gastroenterology as the preferred screening test<sup>[22]</sup>. The principal benefit of colonoscopy is that it allows for a full structural examination of the colon and rectum in a single session and for the detection of colorectal polyps and cancers accompanied by biopsy or polypectomy. Therefore, it has been performed with much higher frequency than all other procedures<sup>[23]</sup>.

However, even in the United States where the technology and procedure are widely available, the colorectal screening participation is still low among average-risk adults in the range of 29.8% to 55.2%<sup>[24]</sup>. The participation rate is also surprisingly low at 40% for people at increased risk of CRC<sup>[25,26]</sup>. The majority of United States adults are not receiving regular age- and risk-appropriate screening due to concerns of cost, risk, and the discomfort and cumbersome preparation associated with the procedure<sup>[27-29]</sup>. The same is true in other European and Asian nations<sup>[2,30-32]</sup>.

Although colonoscopy is the most effective screening method for CRC, there are various reported risks associated with the procedure, including bleeding (1.64 per 1000 patients), perforation (0.85 per 1000), death (0.074 per 1000), missed adenoma (6%-12%), and missed cancer (5%)<sup>[33]</sup>. The observed rate of missed polyps and/or cancer are largely due to variations in polyp size and other factors such as sub-optimal bowel preparation, experience of the endoscopists, and patient anatomical variations<sup>[34]</sup>. When it is taken into consideration that the guideline for the average-risk adult is to undergo colonoscopy every 10 years beginning at age 50<sup>[8,22]</sup> coupled with the rate of missed polyps being between 6% and 12%, there is still risk of developing CRC even when regular colonoscopy screening guidelines are followed.

### **Importance of an alternative screening method for CRC**

The goals of any test are to detect disease early, improve duration and quality of life, reduce mortality and/or mor-

bidity, and augment patient participation for that disease process—all at a very low risk and cost. To this end, the current CRC screening modality based on colonoscopy is severely inadequate. Despite all of the benefits that colonoscopy can offer as a screening procedure for CRC, concerns about its cost, risks, cumbersome preparatory procedure, and willingness of the general public to participate seriously compromise its effect in undermining the global CRC burden<sup>[35-37]</sup>.

In an ideal world, the first line screening should be performed to identify a high risk segment of the population and then use a more extensive test (colonoscopy) on this sub group to reduce incidence of advanced diseases. In other words, it is crucial for the first line screening program to separate the following three entities: the general population (average risk), high risk group, and cancer group. Despite its non-specific nature, the simple FIT, when coupled with colonoscopy, has helped to dramatically reduce cancer incidence and number of deaths - In 100000 average risk patients, this screening has helped to reduce the number of cancer cases from 4875 to 1393, and number of cancer deaths from 1782 to 457<sup>[38]</sup>. Therefore, a more effective and sensitive blood-based biomarker test, supported by evidence from larger studies with solid results, can readily replace the stool-based test.

In order to establish a screening test, it must be evaluated for the following elements: frequency of performance, risk of complications, limitations, and false positive and negative rates. A blood-based test could be ideally used as a first line screening if all these elements were reliably determined and optimized. Colonoscopy would then become the secondary test, not the primary one. There will be greater willingness, by physicians and patients alike, to perform a blood test every several years than to justify the bowel preparation and complications of colonoscopy every 5-10 years.

## **BLOOD-BASED BIOMARKER FOR SCREENING CRC**

Blood vessels are the human body's internal superhighways, for transporting nutrients to all cells in the body and carrying away waste products to avoid toxin buildup. Furthermore, they are also the body's chief communication channel into which signaling molecules such as hormones and cytokines are secreted and released in order to regulate a cascade of effector cell functions on distant sites. It would be ideal, therefore, to take advantage of this superhighway, with all of its abundant signaling molecules, to gauge a patient's health status.

The idea of a blood-based molecular test is appealing because the specimens can be obtained readily in a non-invasive manner, and it can be easily performed for any patient with minimal risk. If it were available, a blood-based test for CRC would reduce the overall cost, risk, and low patient participation issues that are typically associated with colonoscopy<sup>[39]</sup>. The key to developing a

useful blood-based molecular test is to find specific molecular indicators in the blood that are sensitive and specific for the detection of CRC. These indicators can be present in plasma or serum, and any form of molecules, including RNA, DNA, and protein<sup>[40-44]</sup>.

Recent advances in the development of molecular diagnostic technology have allowed an expanding list of potential new screening modalities based on blood specimens to emerge. The available technologies, their current status, and their potential application will be discussed in further detail below.

### **Circulating RNA markers**

RNA was originally thought to be highly labile, easily degradable, and therefore not likely to be stable or detectable outside of the protective cellular environment. However, numerous recent studies have shown that RNA are actually stable outside of cells<sup>[45,46]</sup>, and all species of RNA, including both coding messenger RNA (mRNA)<sup>[47]</sup> and non-coding RNA, which includes microRNA (miRNA) and long non-coding RNA (lncRNA)<sup>[48,49]</sup>, can be extracted and detected in the circulating blood plasma, serum, and other bodily fluids<sup>[50-52]</sup>. Furthermore, RNA expression is highly regulated in normal state but becomes increasingly dysregulated in a pathological state such as cancer<sup>[48,53]</sup>. Therefore, numerous studies have focused on profiling RNA expression, which may correspond to cancer state, and finding the indicator biomarkers for cancers<sup>[54-57]</sup>.

### **mRNA markers**

Various research groups have investigated the potential use of circulating mRNA as markers for cancer. The general experimental strategy is to employ microarray technology for mRNA expression profiling, which is then followed by validation using real time quantitative reverse transcription polymerase chain reaction (RT-qPCR). The specimens used are either mRNA extracted directly from blood serum/plasma or from peripheral blood cells<sup>[58]</sup>. Koprski *et al.*<sup>[47]</sup> demonstrated the possibility of detecting tumor mRNA, tyrosinase, in the serum of malignant melanoma patients although the result remains controversial<sup>[59]</sup>. Tsouma *et al.*<sup>[60]</sup> extracted RNA from peripheral blood cells and used the multiplex RT-qPCR technology to determine the expression of three transcripts (carcino-embryonic antigen, cytokeratin 20 and epidermal growth factor receptor) to determine the disease stage and overall survival of CRC patients. DePrimo *et al.*<sup>[61]</sup> and Twine *et al.*<sup>[62]</sup> performed microarray-based mRNA expression profiling in peripheral blood mononuclear cells in 2003 and proposed some potential markers. However, this research generally remained at a proof-of-concept or pilot study stage, and further follow-up study has been sparse as the strategy they originally employed is now gradually being replaced by the new technology of Next Generation Sequencing (NGS), which will be discussed in more detail later.

### **ColonSentry as CRC screening or risk-assessment test?**

Marshall *et al.*<sup>[63]</sup> from GeneNews Ltd. developed a blood-based test using a seven-gene biomarker panel (*ANXA3*, *CLEC4D*, *LMNB1*, *PRRG4*, *TNFAIP6*, *VNN1* and *IL2RB*) testing RNA extracted from peripheral blood cells. This seven-gene panel was derived from a 196-gene expression profile using 112 CRC patients (including those with stage I, II, III, and IV disease) and 120 controls. The panel was confirmed using 202 CRC patients (from all stages) and 208 controls, all from the Canadian population. They reported a sensitivity of 72% and specificity of 70% for this initial study. Then, they validated the seven-gene profile using 99 CRC patients (presumably from all stages) and 111 controls from the Malaysian population and reported 61% sensitivity and 77% specificity<sup>[64]</sup>. The researchers further validated their panel with an even larger population of 314 CRC patients (from all stages) and 328 controls from Canada and the United States, and they reported a sensitivity of 78% and specificity of 66%<sup>[65]</sup>. GeneNews now offers the ColonSentry test, presumably based on this seven-gene profile, as the world's first commercially available blood test for colon cancer screening, which is licensed to Enzo Clinical Labs of Enzo Biochem for the United States market. The test has recently been approved by the New York State Department of Health as a test to determine a person's risk of having CRC<sup>[66]</sup>.

The ColonSentry molecular diagnostic test is marketed as a risk assessment tool rather than a cancer detection test. Although the experimental design for this seven-gene profile appeared to focus on identifying a pan-CRC marker panel when it profiled and validated a total of 727 CRC patients from all stages (estimated to be 30% stage I, 30% stage II, 30% stage III, and 10% stage IV), there is no mention of any study on high risk individuals, advanced adenomas (AA), or patients with colon polyps that ultimately turned cancerous. It is therefore unclear how a set of pan-CRC markers for all CRC stages can be marketed as a risk assessment test. In any case, the test is considered experimental and investigational with many independent experts still questioning its effectiveness.

### **MiRNA as blood-based cancer markers**

MiRNA are small non-coding RNA about 18-25 nucleotides in size<sup>[67]</sup>. A large body of publications indicates that miRNA regulate gene expression at the post-translational level in almost every biological event and play important roles in tumorigenesis, cancer development, migration and metastasis<sup>[68]</sup>. The differential expression of miRNA has been related to various cancers<sup>[69]</sup>, and efforts have been made to profile the global and circulating miRNA expression patterns associated with various cancers, including breast cancer<sup>[70]</sup>, lung cancer<sup>[71]</sup>, lymphoma<sup>[72]</sup>, ovarian cancer<sup>[73]</sup>, and pancreatic cancer<sup>[74,75]</sup>.

For CRC, studies have accumulated over the past five years that focus on profiling circulating blood plasma or serum miRNA and validating the findings with RT-qP-

CR. Ng *et al.*<sup>76]</sup> was the first group to profile 95 miRNA using a real-time PCR-based array on 5 CRC patients and 5 controls (presumably from the Chinese population in Hong Kong) and to validate the results with 90 CRC patients and 50 healthy controls. They identified miR-17-3p and miR-92 to be elevated significantly in CRC patients with 89% sensitivity and 70% specificity. Wang *et al.*<sup>77]</sup> profiled 742 miRNA using a miRNA microarray on 10 CRC patients and 10 normal controls from the Chinese population and validated the results with 90 CRC patients, 43 AA patients, and 58 healthy donors. They found miR-601 and miR-760 to be decreased in both CRC and AA patients when compared to healthy controls with 83.3% sensitivity and 69.1% specificity. Giráldez *et al.*<sup>78]</sup> performed a genome-wide profiling of 743 miRNA using a miRNA microarray on 21 CRC patients, 20 AA patients, and 20 healthy controls from the Spanish population, and they validated the findings using RT-qPCR with 42 CRC patients, 40 AA patients, and 53 controls. They identified a six-miRNA panel (miR-15b, miR-18a, miR-19a, miR-19b, miR-29a, and miR-335) as being able to differentiate CRC patients from healthy individuals with 78.57% sensitivity and 79.25% specificity, and miR-18a could also differentiate AA patients from healthy individuals with both 80% sensitivity and specificity. Luo *et al.*<sup>79]</sup> used a TaqMan MiRNA array to profile 667 miRNAs on 50 CRC patients and 50 controls from the German population and validated the results with new cohorts of 80 CRC patients compared to 144 controls and 50 AA patients compared to 50 controls. They identified nine miRNA (miR-18a, miR-20a, miR-21, miR-29a, miR-92a, miR-106b, miR-133a, miR-143, and miR145) to be differentially expressed in CRC patients and controls with the area under the accompanying receiver operating characteristic curve reported to be 0.745. The panel of miRNA did not, however, differentiate AA patients from the controls. Kanaan *et al.*<sup>80]</sup> screened for 380 miRNA using microfluidic TaqMan array technology on 20 CRC patients, 9 AA patients (referred to as colorectal adenomas), and 12 healthy donors of mixed racial background in the United States. They then validated the findings with a new cohort of 45 CRC patients, 16 AA patients, and 26 healthy controls; they derived an eight-miRNA panel (miR-15b, miR-17, miR-142-3p, miR-195, miR-331, miR-532-5p and 532-3p, and miR-652) that can distinguish AA patients from controls with 88% sensitivity and 64% specificity, and a three-miRNA panel (miR-431, miR-15b, and miR-139-3p) to differentiate stage IV CRC patients from controls with 93% sensitivity and 74% specificity. Ahmed *et al.*<sup>81]</sup> performed a profiling using miRNA microarray chips covering miRNA based on the published miRBase v17 list (presumed to be 1733 human miRNA) and validated their results using TaqMan RT-qPCR to analyze a panel of miRNA expression both in CRC patient plasma and tissues. They found nine miRNA (miR-7, miR-17-3p, miR-20a, miR-21, miR-92a, miR-96, miR-183, miR-196a and miR-214) to have increased expression and

six miRNA (miR-124, miR-127-3p, miR-138, miR-143, miR-146a, and miR-222) to have reduced expression in both CRC patient plasma and tissues with 90% sensitivity and 95% specificity.

A few studies selected their miRNA markers based on published literature and re-confirmed the results with RT-qPCR assays. Huang *et al.*<sup>82]</sup> measured the levels of twelve miRNAs (miR-17-3p, -25, -29a, -92a, -134, -146a, -181d, -191, -221, -222, -223, and -320a) studied in the literature in 120 CRC patients, 37 AA patients, and 59 healthy controls from the Chinese population, and they confirmed miR-29a and miR-92a as potential indicators for CRC with 83% sensitivity and 84.7% specificity. Similarly, Liu *et al.*<sup>83]</sup> measured the levels of five miRNAs (miR-18a, -21, -31, -92a, and -106a) in serum samples from 200 CRC patients, 50 AA patients, and 80 healthy controls from the Chinese population and identified miR-92a along with miR-21 to be both significantly higher in CRC patients with 68% sensitivity and 91.2% specificity. Pu *et al.*<sup>84]</sup> measured miRNA expression levels of three target miRNAs (miR-21, -221, and -222) in 103 CRC patients and 37 controls from the Chinese population and found elevated expression of miR-221 in CRC patients with 86% sensitivity and 41% specificity. Wang *et al.*<sup>85]</sup> screened three miRNAs (miR-29a, -92a, and -17-3p) in 38 metastatic CRC and 36 primary CRC patients, assumed to be from the Chinese population, but did not utilize healthy controls. They found miR-29a to be higher in CRC patients with liver metastases than in primary CRC patients with sensitivity and specificity of 75%, and hence miR-29a may be useful in discriminating metastatic from non-metastatic CRC patients. Cheng *et al.*<sup>86]</sup> screened three miRNAs (miR-21, -92, and -141) using a cohort of 102 CRC patients and an age-matched cohort of healthy donors of mixed racial background from the United States population, validated their findings using 156 CRC patients and matched controls from the Chinese population, and found miR-141 to be higher in cases of advanced CRC (stage IV) with 90.9% sensitivity and 77.1% specificity.

As summarized in Table 1, there are a total of 38 miRNA that have been studied and proposed as potential biomarkers for CRC in the publications discussed above. In general, most of these studies focused on early stage CRC patients while some also included borderline AA patients. When pooling from all the studies mentioned here, sensitivities in the range of 68%-91% were reported, but the majority (in 9 out of 12 cases) observed sensitivities in the 83%-91% range. Reported specificities were in the range of 41%-95%, but the majority (also in 9 out of 12 cases) were in the 70%-95% range. Some miRNA, including miR-15b, miR-17-3p, miR-18a, miR-20a, miR-21, miR-29a, and miR-92a, have been proposed by more than one group of investigators. One unique miRNA, miR-21, might actually be a useful pan-cancer marker as it is similarly up regulated in other cancers<sup>87]</sup>. However, most of these studies have not yet been evalu-

**Table 1 Potential blood microRNA markers**

MiRNA	AA?	Ref.
Upregulated in primary CRC		
miR-7		[81]
miR-15b	√	[78,80]
miR-17-5p	√	[80]
miR-17-3p		[76,81]
miR-18a	√	[78,79]
miR-19a		[78]
miR-19b		[78]
miR-20a		[79,81]
miR-21		[79,81,83,87,160-163]
miR-29a		[78,79,82]
miR-92a		[76,79,81-83]
miR-96		[81]
miR-106b		[79]
miR-133a		[79]
miR-142-3p	√	[80]
miR-143		[79]
miR-145		[79]
miR-183		[81]
miR-195	√	[80]
miR-196a		[81]
miR-214		[81]
miR-221		[84]
miR-331	√	[80]
miR-335		[78]
miR-532-5p	√	[80]
miR-532-3p	√	[80]
miR-652	√	[80]
miR-1246		[164]
Upregulated in metastatic CRC		
miR-15b	√	[80]
miR-29a		[85]
miR-139-3p		[80]
miR-141		[86]
miR-431		[80]
Downregulated in primary CRC		
miR-124		[81]
miR-127-3p		[81]
miR-138		[81]
miR-143		[81]
miR-146a		[81]
miR-222		[81]
miR-601	√	[77]
miR-760	√	[77]

AA: Able to differentiate advanced adenoma; CRC: Colorectal cancer; MiRNA: MicroRNA.

ated beyond the proof-of-principle and pilot stage, and not all miRNA markers were subsequently studied and confirmed by other groups. For example, Faltejsova *et al.*<sup>[88]</sup> was not able to confirm the potency of miR-17-3p, miR-29a, miR-92a, and miR-135b as biomarkers for CRC. Luo *et al.*<sup>[79]</sup> and Ahmed *et al.*<sup>[81]</sup> found differential miR-143 expression in their respective studies. Other potential markers such as miR-17-3p, miR-18a, miR-21, miR-92, and miR-221 were not confirmed in follow-up studies by other groups<sup>[82-84,86]</sup>.

Clearly, it is comprehensible that different experimental designs, procedures and methods, endogenous controls, patient populations, instrumentation and lab personnel could contribute to the seemingly contradicting results that have been published thus far. Nevertheless,

the 38 candidate miRNA markers together can be further investigated using currently available technology, such as the TaqMan RT-qPCR profile platform already utilized by some of the research groups. It is possible, therefore, to coordinate a multicenter clinical trial involving different research groups and incorporating patient populations from a wide variety of backgrounds. It would be critical to synchronize specimen collection, processing procedures, and storage conditions for the collected specimens. The experimental design should also be based on a coordinated and synchronized set of experimental procedures and instrumentation that utilize the same endogenous control(s). The validity of each of the 38 miRNA markers as a tool for diagnosing CRC can then be evaluated for their potential future application.

### NEXT GENERATION SEQUENCING

Since the first drafts of the human genome were published in 2001, sequencing technology has advanced at an ever rapid pace<sup>[89]</sup>. The cost of sequencing has decreased from about \$1000 per megabase of DNA sequence when the first generation Sanger-based sequencing machine was used in 2001, down to \$0.1 per megabase of DNA sequence using the next generation sequencing machine in 2013<sup>[90,91]</sup>. The cost for personal whole-genome sequencing has dropped from \$100000000 in 2001 to \$4000 (sequencing offered by Illumina, Inc.) in 2013, and it could possibly be driven further down to \$1000 in the imminent future<sup>[92]</sup>. The availability of the NGS has revolutionized biomarker studies<sup>[93]</sup>. It is now possible to perform direct RNA sequencing (RNA-seq)<sup>[94]</sup> to sequence the whole transcriptome, which includes the entire set of all RNA molecules-coding RNA (mRNA, rRNA, tRNA) and non-coding RNA (miRNA, lncRNA, and other small RNA species)<sup>[94,95]</sup>.

RNA-seq is very versatile and has been used to analyze tissue RNA biomarkers in breast cancer<sup>[96]</sup>, hepatocellular carcinoma<sup>[97]</sup>, lymphoma<sup>[98,99]</sup>, melanoma<sup>[100,101]</sup>, and prostate cancer<sup>[100]</sup>. RNA-seq has also been used to analyze gene expression signatures associated with survival<sup>[100]</sup>, smoking status<sup>[102]</sup>, and altered expression associated with *KRAS* mutation<sup>[103]</sup> in lung cancer. In terms of CRC, Wu *et al.*<sup>[104]</sup> have performed transcriptome profiling comparing CRC, adjacent normal, and distant normal tissues and have identified 5 differentially expressed genes, including *ITGB5*, *COL1A1*, *FN1*, *SPP1*, and *COL3A1*, as well as alternative splicing, isoforms, and gene fusion events. It is anticipated that with the ability to extract and sequence RNA from blood plasma, more studies on blood-based RNA markers, based on RNA-seq technology, will soon emerge.

### lncRNA markers

Given the increased availability of RNA-seq technology, it is now possible to study the lncRNA, which was dismissed as “junk” in the past but has now been found to regulate gene expression and cellular functions<sup>[105]</sup>.

lncRNA, like its miRNA counterpart, plays major roles in tumor suppression and oncogenic functions and has been found to be dysregulated in human cancers<sup>[106]</sup>. Therefore, its potential role as biomarkers for cancer and other diseases has been investigated extensively<sup>[107,108]</sup>. As an example, Prostate cancer antigen (PCA3, also known as DD3) is a non-coding RNA that is highly sensitive and now used as a biomarker for the urine diagnostic test of prostate cancer<sup>[109-111]</sup>.

In terms of CRC, research is currently focused on the role of lncRNA as tissue biomarkers. Ge *et al.*<sup>[112]</sup> found that Prostate cancer-associated ncRNA transcripts 1 was upregulated in CRC tissue but not in adjacent normal tissue. Zhai *et al.*<sup>[113]</sup> found that long intergenic noncoding RNA-p21 was upregulated in CRC tissue, and the expression level seemingly correlated with tumor progression (higher expression in later stages). Ling *et al.*<sup>[114]</sup> showed a novel lncRNA-CCAT2 was highly overexpressed in CRC, and it was shown to be promoting tumor growth, metastasis and chromosomal instability. Kogo *et al.*<sup>[115]</sup> demonstrated that expression of lncRNA-HOTAIR, which is known to reprogram chromatin organization and promote breast cancer metastasis<sup>[116]</sup>, is also higher in stage IV CRC patients with liver metastases. Xu *et al.*<sup>[117]</sup> found the lncRNA-human metastasis associated lung adenocarcinoma transcript 1 (MALAT-1) to be dysregulated in cancer, and the mutation on the 3' end of MALAT-1 is apparently tumorigenic. It is conceivable that RNA-seq technology can help facilitate further investigation into lncRNA functions and exploration of blood-circulating lncRNA as potential biomarkers for CRC and other cancers in the future.

## BLOOD-BASED CIRCULATING DNA MARKERS

The presence of tumor DNA in circulating blood (plasma or serum) has been documented dating back to 1977<sup>[118]</sup>. Cell-free DNA (cfDNA) was thought to be released from either apoptotic or necrotic cancer cells, from direct secretion or as a byproduct of phagocytosis from macrophages or other scavenger cells<sup>[119,120]</sup>. Originally, it received little attention, but with recent advances in next generation sequencing (NGS) technology, it has been explored extensively for the potential application to cancer detection<sup>[121]</sup>. In general, the studies of cfDNA as cancer biomarkers focus on monitoring the presence of promoter hypermethylation, aberrant tumor DNA mutation, microsatellite alterations, and mitochondria DNA in blood circulation. The validity of each approach will be discussed below.

### Aberrant DNA methylation as markers

Aberrant DNA methylation has been associated with tumorigenesis as a consequence of the alteration it causes in gene expression<sup>[122,123]</sup>. For example, hypermethylation of tumor suppressor promoter genes would cause inap-

propriate gene silencing and therefore lead to cancer<sup>[124]</sup>. In general, DNA methylation is thought to be associated with an early event in tumorigenesis and has therefore been proposed as a potential early cancer detection marker<sup>[123,125]</sup>. The research strategy typically focuses on using methylation specific PCR (MSP) to study hypermethylation of methylation sites, in CpG dinucleotides or in CpG islands, in the promoters of tumor suppressor genes<sup>[124,126]</sup>. In the context of CRC, Nakayama *et al.*<sup>[127]</sup> and Lecomte *et al.*<sup>[128]</sup> both monitored the hypermethylation of the promoter of tumor suppressor gene *p16* and found the plasma in 21 of 31 (68%) patients and 31 of 45 (69%) patients, respectively, to be positive. Grady *et al.*<sup>[129]</sup> found aberrant hypermethylation of the human MutL homolog 1 (*bMLH1*) promoter in the sera of 9 out of 19 (47%) cases of CRC. Leung *et al.*<sup>[130]</sup> monitored promoter hypermethylation in three genes, adenomatous polyposis coli (*APC*), *bMLH1*, and *helicase-like transcription factor*, and found at least one of the three genes with methylated promoter DNA in the sera of 28 out of 49 (57%) CRC patients. Additional genes monitored for tumor-related promoter hypermethylation, including the putative metastasis suppressor gene *death-associated protein kinase*, the detoxification gene *glutathione S-transferase P1*, the DNA repair gene *O<sup>6</sup>-methylguanine-DNA-methyltransferase*, and *p14-ARF* in other cancers exhibit a detection rate that is generally in the range of 42% to 73%<sup>[131-133]</sup>. It is conceivable that NGS technology can be coupled with MSP to identify a pool of tumor suppressing genes silenced in association with early stage CRC and AA, test their corresponding promoter methylation, and generate a set of candidate markers based on epigenetic changes as a screening panel for CRC in the future.

### Aberrant tumor DNA mutation markers

The NGS technology has been employed for somatic mutation analysis in CRC<sup>[134]</sup>, particularly on several high mutation frequency genes, such as *K-RAS*<sup>[128,135,136]</sup>, *TP53*<sup>[137]</sup>, and *APC*<sup>[138]</sup>. However, the percentage of circulating tumor DNA is relatively low when compared to wild-type DNA<sup>[139]</sup>. For example, Diehl *et al.*<sup>[138]</sup> has shown that in advanced CRC, the mutated *APC* DNA fragment is found to be in the range of 1.9% to 27% of cfDNA but only 0.01% to 0.12% in early stage CRC. Even with direct sequencing technology, it does not allow reliable detection of less than 25% mutant signal in a background of wild-type DNA<sup>[140]</sup>. Furthermore, the tumor-associated mutations are often unique with each patient<sup>[141,142]</sup>, and therefore, based on the current available technology, it is less likely to develop a low cost and highly sensitive comprehensive test to cover all somatic mutations for early cancer detection.

### Microsatellite alterations as markers

Microsatellite alterations, which include microsatellite instability (MSI) and loss of heterozygosity (LOH), are known to be associated with tumorigenesis and cancer

progression and therefore were proposed as potential tumor markers detectable in cfDNA<sup>[143]</sup>. MSI analysis focuses on measuring the specific polymorphic tetra-nucleotide repeat and/or dinucleotide markers that are located in regions frequently shifted or altered in cancer, and LOH analysis focuses on the loss of specific chromosomal regions bearing tumor suppressors. Hibi *et al.*<sup>[141]</sup> examined microsatellite alterations and found LOH or microsatellite shift of at least one locus (18a, 17p, and 8p) in 35 of 44 (80%) primary CRC tumors, but none of the LOH or microsatellite shifts were detected in the corresponding serum DNA. Several other groups focused on different cancers with most success in metastatic cancers<sup>[143,144]</sup>. In general, microsatellite alteration analysis exhibits relatively low sensitivity and specificity in detecting early stage cancer.

### **Circulating mitochondrial DNA as markers**

There are generally a few hundreds of copies of mitochondrial DNA in each cell<sup>[145]</sup>. Due to its multi-copy nature, mtDNA is frequently found to be heteroplasmic, with a heterogeneous mixture of polymorphic variants. In cancer cells, mtDNA harbor further heteroplasmic alterations associated specifically with cancer, especially in the highly variable D-loop (displacement loop) region. With the NGS, the approaches generally focused on either differential copy number of mtDNA versus gDNA, or mtDNA alteration and tumor-associated mtDNA mutations<sup>[146]</sup>. For CRC, Hibi *et al.*<sup>[147]</sup> has studied mtDNA alternation in early CRC patients and found that 7 out of 77 (9%) CRC tissues contained true somatic mutations in the D-loop region, but only one out of these 7 positive patients (14%) were noted to have mtDNA alterations in their serum DNA. Due to of the relatively low detection rate of early stage cancer, most studies therefore focused on its potential application in metastatic cancers<sup>[148-153]</sup>.

## **IDENTIFICATION OF BLOOD-BASED PROTEIN MARKERS**

The study of blood-based protein markers in general focuses on proteins secreted, shed or leaking from cancer cells into the blood stream. This is generally referred to as “cancer secretome”<sup>[154]</sup>. The cancer secretome can be studied comprehensively by several mass spectrometric technologies. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and HPLC-electrospray ionization mass spectrometry (ESI-MS) analyze biomolecules in biological fluids<sup>[155,156]</sup>. Surface-enhanced laser desorption ionization-time of flight mass spectrometry (SELDI-TOF MS) can be used as a serum protein profiler to identify new biomarkers<sup>[157]</sup>. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) can fractionate and identify the specific molecules of interest<sup>[154]</sup>. There is also an Aptamer proteomic technology that can be used to identify biomarkers for cancer<sup>[158]</sup>. Many candidate protein biomarkers have been generated

based on these technologies.

However, the application of these technologies remains research-oriented. The potency of their translational capability in clinical and diagnostic application requires further investigation<sup>[159]</sup>.

## **CONCLUSION**

Early screening of CRC is clearly the most effective way to combat the anticipated increase of global CRC morbidity and mortality. Despite all recent technological advances, the currently available screening modalities remain archaically similar to 33 years ago. The most effective screening modality today is through the invasive procedure of colonoscopy. However, even in the United States, where the procedure is widely available and publicized, covered by most medical insurance plans, and recommended by medical professionals and practitioners, the participation rate is still pathetically low. It is conceivable that the participation rate would not fare better even if it were widely available on a global scale. Clearly, a new first line CRC screening procedure that is inexpensive, low risk, highly sensitive, and does not require cumbersome preparation is desirable.

A blood-based screening test for CRC would be an attractive alternative to colonoscopy if it were available because it is essentially non-invasive and relatively painless to the patient. Ideally, a blood-based test can be a useful first line screening tool for the general population at average risk, thereby separating out high risk and CRC patient groups. However, for patients with known high risk factors, including family history of CRC, familial adenomatous polyposis, hereditary nonpolyposis CRC, inflammatory bowel disease, history of polyps, or previous CRC, colonoscopy should still be the primary method of screening and follow-up starting at age 50, although a blood-based test can still be used for screening these patients earlier at age 40. In short, circumstances under which a blood-based screening test is used should be determined based on the sensitivity and specificity of the methodology developed in the future.

The key to establishing a good blood-based test is to find highly sensitive and specific biomarkers in the blood. As discussed in this review, various types of biomarkers have been proposed and explored by many research groups to varying degrees. Table 2 summarizes the sensitivity, specificity, and estimated cost for the types of stool-based tests, structural exams, and potential blood-based tests as discussed in this review. The ColonSentry® seven-gene mRNA biomarker panel is the first commercially available blood test that is supposed to determine the risk of developing CRC. The sensitivity and specificity for this “risk assessment” are 78% and 66% respectively. As shown in Table 2, among all the biomarker types, the miRNA markers demonstrated the greatest potential because most publications reported a relatively high sensitivity (83%-91%) and specificity (70%-95%) rate, utilized mostly AA and early stage CRC patient, and

Table 2 Comparison of colorectal cancer screening tests

Test name	Cost	Procedure type	Prep?	Sensitivity	Specificity	Note	Ref.
gFOBT	\$5 <sup>3</sup>	Stool test	Yes <sup>1</sup>	12% <sup>2</sup> and 40%	98%	Hemoccult II	[165]
iFOBT/FIT	\$22 <sup>3</sup>	Stool test	Yes <sup>1</sup>	22% <sup>2</sup> and 70%	95%		[165]
Fx. Sigmoidoscopy	\$500-\$750 <sup>3</sup>	Invasive	Yes	95% <sup>2</sup> and 95%	92%		[165]
Colonoscopy	\$800-\$1600 <sup>3</sup>	Invasive	Yes	95% <sup>2</sup> and 98%	90%		[165,166]
DCBE	\$250-\$500 <sup>3</sup>	X-ray	Yes	48% <sup>2</sup>	90%	Not recommended by USPSTF	[166]
CTC	\$400-\$800 <sup>3</sup>	CT-scan	Yes	59% <sup>2</sup>	96%	Not recommended by USPSTF	[166]
Blood-based test							
ColonSentry®	\$350	blood-test	No	78%	66%	GeneNews/Enzo Biochem	[66]
MiRNA (5-gene)	Est. \$250 <sup>4</sup>	blood-test	No	Est. 83%-91%	Est. 70%-95%		
LncRNA (1-gene)	\$385.00 <sup>5</sup>	blood-test	No	N/A	N/A		
DNA methylation	Est. \$250 <sup>4</sup>	blood-test	No	Est. 42%-73%	Est. 42%-73%		

<sup>1</sup>Required to clean colon; <sup>2</sup>For detecting advanced adenoma at  $\geq 10$  mm; <sup>3</sup>Cost estimated from Colon Cancer Alliance website (<http://www.ccalliance.org/index.html>); <sup>4</sup>Cost estimated based on The Valley Hospital Histology Lab charge; <sup>5</sup>Cost estimated based on PCA3 test offered by GD Specialized Diagnostics. Fx. Sigmoidoscopy: Flexible Sigmoidoscopy; DCBE: Double-contrast barium enema; CTC: Computed tomographic colonography; USPSTF: United States Preventive Services Task Force; gFOBT: Guaiac-based Fecal Occult Blood Test; iFOBT: Immunochemical Fecal Occult Blood Test; FIT: Fecal Immunochemical Test; MiRNA: MicroRNA; LncRNA: Long non-coding RNA; CT: Computed tomography; N/A: Data not available; PCA3: Prostate cancer antigen 3.

studied a wide variety of patient populations. Therefore, a multi-center clinical trial with synchronized experimental procedures that tested all 38 miRNA listed in Table 1 could be considered. On the other hand, the aberrant DNA methylation analyses on promoters of tumor suppressors also demonstrated a high potential to be developed into a cancer screening test. With available NGS technology and MSP showing relatively high sensitivity and specificity (42%-73%), it is now possible to explore more tumor-specific promoters, which might have higher sensitivity and specificity and eventually be developed into a screening test.

On the other hand, although research studies of lncRNA markers using NGS are still at the early stage, it has a great potential to be developed into a CRC screening test as well. It is especially encouraging to see one of the lncRNA, PCA3, is now used routinely as a prognostic marker for prostate cancer. With the wider availability of NGS, it is anticipated that more studies will be undertaken to generate new candidate genes and biomarkers, which would possibly lead to a future diagnostic test for CRC.

## ACKNOWLEDGMENTS

We thank the Research Cancer Committee, Dr. Barbara Heerd, PhD for the helpful discussion and input, and Dr. Madhuri Ramanathan, PhD of the Valley Hospital Histology Lab for input on lab tests. We also thank Mr. Ankur A. Patel for his assistance during the writing process.

## REFERENCES

- 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
- 2 Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. *World J Gastrointest Oncol* 2012; **4**: 68-70 [PMID: 22532878 DOI: 10.4251/wjgo.v4.i4.68]
- 3 Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. *Lancet Oncol* 2012; **13**: 790-801 [PMID: 22658655 DOI: 10.1016/S1470-2045(12)70211-5]
- 4 Population Division. World Population Prospects: The 2012 Revision, Highlights and Advance Tables. New York: United Nations Department of Economic and Social Affairs, 2013
- 5 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet* 1997; **349**: 1269-1276 [PMID: 9142060 DOI: 10.1016/S0140-6736(96)07493-4]
- 6 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
- 7 Eddy D. ACS report on the cancer-related health checkup. *CA Cancer J Clin* 1980; **30**: 193-240 [PMID: 6774802]
- 8 Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin* 2008; **58**: 130-160 [PMID: 18322143 DOI: 10.3322/CA.2007.0018]
- 9 U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. *Am Fam Physician* 2002; **66**: 2287-2290 [PMID: 12507168]
- 10 Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. *Gastroenterology* 2006; **130**: 1872-1885 [PMID: 16697750 DOI: 10.1053/j.gastro.2006.03.012]
- 11 Diaz JA, Slomka T. State of the Art Review: Colorectal Cancer Screening. *Am J Lifestyle Med* 2012; **6**: 196-203 [PMID: 23539676 DOI: 10.1177/1559827611413243]
- 12 Steinwachs D, Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P, Lave JR, Laveist TA, Ness RB, Optican RJ, Virnig BA. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. *Ann Intern Med* 2010; **152**: 663-667 [PMID: 20388702 DOI: 10.7326/0003-4819-152-10-201005180-00237]

- 13 **Fraser CG**, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. *Lancet Oncol* 2006; **7**: 127-131 [PMID: 16455476 DOI: 10.1016/S1470-2045(05)70473-3]
- 14 **Hewitson P**, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* 2008; **103**: 1541-1549 [PMID: 18479499 DOI: 10.1111/j.1572-0241.2008.01875.x]
- 15 **Health Quality Ontario**. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. *Ont Health Technol Assess Ser* 2009; **9**: 1-40 [PMID: 23074514]
- 16 **Schnell T**, Aranha GV, Sontag SJ, Tode R, Reid S, Chejfec G, Karpf J, Levine G. Fecal occult blood testing: a false sense of security? *Surgery* 1994; **116**: 798-802; discussion 802-803 [PMID: 7940181]
- 17 **Wong CK**, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. *Int J Colorectal Dis* 2012; **27**: 1657-1664 [PMID: 22696204 DOI: 10.1007/s00384-012-1518-3]
- 18 **Roslani AC**, Abdullah T, Arumugam K. Screening for colorectal neoplasias with fecal occult blood tests: false-positive impact of non-dietary restriction. *Asian Pac J Cancer Prev* 2012; **13**: 237-241 [PMID: 22502676]
- 19 **Mant D**, Fitzpatrick R, Hogg A, Fuller A, Farmer A, Verne J, Northover J. Experiences of patients with false positive results from colorectal cancer screening. *Br J Gen Pract* 1990; **40**: 423-425 [PMID: 2271264]
- 20 **Allison JE**, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. *N Engl J Med* 1996; **334**: 155-159 [PMID: 8531970 DOI: 10.1056/NEJM199601183340304]
- 21 **Heresbach D**, Manfredi S, D'halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. *Eur J Gastroenterol Hepatol* 2006; **18**: 427-433 [PMID: 16538116]
- 22 **Rex DK**, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol* 2009; **104**: 739-750 [PMID: 19240699 DOI: 10.1038/ajg.2009.104]
- 23 **Meissner HI**, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 389-394 [PMID: 16492934 DOI: 10.1158/1055-9965.EPI-05-0678]
- 24 **Beydoun HA**, Beydoun MA. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. *Cancer Causes Control* 2008; **19**: 339-359 [PMID: 18085415 DOI: 10.1007/s10552-007-9100-y]
- 25 **Ait Ouakrim D**, Lockett T, Boussioutas A, Hopper JL, Jenkins MA. Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis. *Fam Cancer* 2013; **12**: 459-472 [PMID: 23700069 DOI: 10.1007/s10689-013-9658-3]
- 26 **Cummings LC**, Cooper GS. Colorectal cancer screening: update for 2011. *Semin Oncol* 2011; **38**: 483-489 [PMID: 21810507 DOI: 10.1053/j.seminoncol.2011.05.002]
- 27 **Wee CC**, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physician counseling. *Prev Med* 2005; **41**: 23-29 [PMID: 15916989 DOI: 10.1016/j.ypmed.2004.11.004]
- 28 **Boehm JE**, Rohan EA, Preissle J, DeGroff A, Glover-Kudon R. Recruiting patients into the CDC's Colorectal Cancer Screening Demonstration Program: strategies and challenges across 5 sites. *Cancer* 2013; **119** Suppl 15: 2914-2925 [PMID: 23868486 DOI: 10.1002/cncr.28161]
- 29 **Ling BS**, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitudes toward colorectal cancer screening tests. *J Gen Intern Med* 2001; **16**: 822-830 [PMID: 11903761]
- 30 **Zavoral M**, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P. Colorectal cancer screening in Europe. *World J Gastroenterol* 2009; **15**: 5907-5915 [PMID: 20014454]
- 31 **Sieg A**, Friedrich K. Perspectives of colorectal cancer screening in Germany 2009. *World J Gastrointest Endosc* 2009; **1**: 12-16 [PMID: 21160645 DOI: 10.4253/wjge.v1.i1.12]
- 32 **Deng SX**, Gao J, An W, Yin J, Cai QC, Yang H, Li ZS. Colorectal cancer screening behavior and willingness: an outpatient survey in China. *World J Gastroenterol* 2011; **17**: 3133-3139 [PMID: 21912456 DOI: 10.3748/wjg.v17.i26.3133]
- 33 **Levin TR**, Corley DA. Colorectal-cancer screening--coming of age. *N Engl J Med* 2013; **369**: 1164-1166 [PMID: 24047066 DOI: 10.1056/NEJMe1308253]
- 34 **Steele SR**, Johnson EK, Champagne B, Davis B, Lee S, Rivadeneira D, Ross H, Hayden DA, Maykel JA. Endoscopy and polyps-diagnostic and therapeutic advances in management. *World J Gastroenterol* 2013; **19**: 4277-4288 [PMID: 23885138 DOI: 10.3748/wjg.v19.i27.4277]
- 35 **Frazier AL**, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. *JAMA* 2000; **284**: 1954-1961 [PMID: 11035892]
- 36 **Sonnenberg A**, Delcò F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. *Ann Intern Med* 2000; **133**: 573-584 [PMID: 11033584]
- 37 **Tsoi KK**, Ng SS, Leung MC, Sung JJ. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. *Aliment Pharmacol Ther* 2008; **28**: 353-363 [PMID: 18638075 DOI: 10.1111/j.1365-2036.2008.03726.x]
- 38 **Heitman SJ**, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. *PLoS Med* 2010; **7**: e1000370 [PMID: 21124887 DOI: 10.1371/journal.pmed.1000370]
- 39 **Debey-Pascher S**, Chen J, Voss T, Staratschek-Jox A. Blood-based miRNA preparation for noninvasive biomarker development. *Methods Mol Biol* 2012; **822**: 307-338 [PMID: 22144209 DOI: 10.1007/978-1-61779-427-8\_22]
- 40 **Kumar S**, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. *Biomarkers* 2006; **11**: 385-405 [PMID: 16966157 DOI: 10.1080/13547500600775011]
- 41 **Chatterjee SK**, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. *Future Oncol* 2005; **1**: 37-50 [PMID: 16555974 DOI: 10.1517/14796694.1.1.37]
- 42 **Tänzer M**, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. *Pharmacol Ther* 2013; **140**: 133-147 [PMID: 23791941 DOI: 10.1016/j.pharmthera.2013.06.005]
- 43 **Goulart BH**, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. *Clin Cancer Res* 2007; **13**: 6719-6726 [PMID: 18006773 DOI: 10.1158/1078-0432.CCR-06-2860]
- 44 **Zeestraten EC**, Kuppen PJ, van de Velde CJ, Marijnen CA. Prediction in rectal cancer. *Semin Radiat Oncol* 2012; **22**: 175-183 [PMID: 22385923 DOI: 10.1016/j.semradonc.2011.12.005]
- 45 **Lo KW**, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjeltn NM, Lee JC, Huang DP. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. *Clin Chem* 1999; **45**: 1292-1294 [PMID: 10430801]
- 46 **Tsui NB**, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. *Clin Chem* 2002; **48**: 1647-1653 [PMID: 12324479]
- 47 **Kopreski MS**, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. *Clin Cancer Res* 1999; **5**: 1961-1965 [PMID:

- 10473072]
- 48 **Cortez MA**, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. *Nat Rev Clin Oncol* 2011; **8**: 467-477 [PMID: 21647195 DOI: 10.1038/nrclinonc.2011.76]
  - 49 **Van Roosbroeck K**, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. *Expert Rev Mol Diagn* 2013; **13**: 183-204 [PMID: 23477558 DOI: 10.1586/erm.12.134]
  - 50 **Sourvinou IS**, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. *J Mol Diagn* 2013; **15**: 827-834 [PMID: 23988620 DOI: 10.1016/j.jmoldx.2013.07.005]
  - 51 **Mitchell PS**, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci USA* 2008; **105**: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]
  - 52 **Weber JA**, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. *Clin Chem* 2010; **56**: 1733-1741 [PMID: 20847327 DOI: 10.1373/clinchem.2010.147405]
  - 53 **Nicoloso MS**, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs--the micro steering wheel of tumour metastases. *Nat Rev Cancer* 2009; **9**: 293-302 [PMID: 19262572 DOI: 10.1038/nrc2619]
  - 54 **Chen X**, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008; **18**: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
  - 55 **Shen J**, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. *Cancer Lett* 2013; **329**: 125-136 [PMID: 23196059 DOI: 10.1016/j.canlet.2012.11.001]
  - 56 **Coskun M**, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease--pathogenesis, diagnostics and therapeutics. *World J Gastroenterol* 2012; **18**: 4629-4634 [PMID: 23002331 DOI: 10.3748/wjg.v18.i34.4629]
  - 57 **Ganepola GA**, Mazziotta RM, Weeresinghe D, Corner GA, Parish CJ, Chang DH, Tebbutt NC, Murone C, Ahmed N, Augenlicht LH, Mariadason JM. Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors. *Clin Exp Metastasis* 2010; **27**: 1-9 [PMID: 19882219 DOI: 10.1007/s10585-009-9295-2]
  - 58 **Chang DH**, Rutledge JR, Patel AA, Heerdt BG, Augenlicht LH, Korst RJ. The effect of lung cancer on cytokine expression in peripheral blood mononuclear cells. *PLoS One* 2013; **8**: e64456 [PMID: 23762239 DOI: 10.1371/journal.pone.0064456]
  - 59 **Quaglino P**, Savoia P, Osella-Abate S, Bernengo MG. RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. *Expert Rev Mol Diagn* 2004; **4**: 727-741 [PMID: 15347265 DOI: 10.1586/14737159.4.5.727]
  - 60 **Tsouma A**, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. *World J Gastroenterol* 2010; **16**: 5965-5974 [PMID: 21157973]
  - 61 **DePrimo SE**, Wong LM, Khattry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM, Cherrington JM. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. *BMC Cancer* 2003; **3**: 3 [PMID: 12657164]
  - 62 **Twine NC**, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. *Cancer Res* 2003; **63**: 6069-6075 [PMID: 14522937]
  - 63 **Marshall KW**, Mohr S, Khettabi FE, Nossova N, Chao S, Bao W, Ma J, Li XJ, Liew CC. A blood-based biomarker panel for stratifying current risk for colorectal cancer. *Int J Cancer* 2010; **126**: 1177-1186 [PMID: 19795455 DOI: 10.1002/ijc.24910]
  - 64 **Yip KT**, Das PK, Suria D, Lim CR, Ng GH, Liew CC. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. *J Exp Clin Cancer Res* 2010; **29**: 128 [PMID: 20846378 DOI: 10.1186/1756-9966-29-128]
  - 65 **Chao S**, Ying J, Liew G, Marshall W, Liew CC, Burakoff R. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study. *J Exp Clin Cancer Res* 2013; **32**: 44 [PMID: 23876008 DOI: 10.1186/1756-9966-32-44]
  - 66 **Novak DJ**, Liew GJ, Liew CC. GeneNews Limited: bringing the blood transcriptome to personalized medicine. *Pharmacogenomics* 2012; **13**: 381-385 [PMID: 22379995 DOI: 10.2217/pgs.12.12]
  - 67 **Sayed D**, Abdellatif M. MicroRNAs in development and disease. *Physiol Rev* 2011; **91**: 827-887 [PMID: 21742789 DOI: 10.1152/physrev.00006.2010]
  - 68 **Lee YS**, Dutta A. MicroRNAs in cancer. *Annu Rev Pathol* 2009; **4**: 199-227 [PMID: 18817506 DOI: 10.1146/annurev.pathol.4.110807.092222]
  - 69 **Krutovskikh VA**, Herceg Z. Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. *Bioessays* 2010; **32**: 894-904 [PMID: 21105295]
  - 70 **Chen XQ**, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. *Clin Cancer Res* 2000; **6**: 3823-3826 [PMID: 11051224]
  - 71 **Shen J**, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. *Lab Invest* 2011; **91**: 579-587 [PMID: 21116241 DOI: 10.1038/labinvest.2010.194]
  - 72 **Lawrie CH**, Gal S, Dunlop HM, Pushkaran B, Higgins AP, Pulford K, Banham AH, Pezzella F, Boulwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol* 2008; **141**: 672-675 [PMID: 18318758 DOI: 10.1111/j.1365-2141.2008.07077.x]
  - 73 **Kulasingam V**, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. *Nat Rev Cancer* 2010; **10**: 371-378 [PMID: 20383179 DOI: 10.1038/nrc2831]
  - 74 **Liu R**, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. *Clin Chem* 2012; **58**: 610-618 [PMID: 22194634 DOI: 10.1373/clinchem.2011.172767]
  - 75 **Ganepola GA**, Rutledge JR, Suman P, Yiegpurksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. *World J Gastrointest Oncol* 2014; **6**: 22-33 [PMID: 24578785 DOI: 10.4251/wjgo.v6.i1.22]
  - 76 **Ng EK**, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. *Gut* 2009; **58**: 1375-1381 [PMID: 19201770 DOI: 10.1136/gut.2008.167817]
  - 77 **Wang Q**, Huang Z, Ni S, Xiao X, Xu Q, Wang L, Huang D, Tan C, Sheng W, Du X. Plasma miR-601 and miR-760 are

- novel biomarkers for the early detection of colorectal cancer. *PLoS One* 2012; **7**: e44398 [PMID: 22970209 DOI: 10.1371/journal.pone.0044398]
- 78 **Giráldez MD**, Lozano JJ, Ramírez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. *Clin Gastroenterol Hepatol* 2013; **11**: 681-8.e3 [PMID: 23267864 DOI: 10.1016/j.cgh.2012.12.009]
- 79 **Luo X**, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. *PLoS One* 2013; **8**: e62880 [PMID: 23690963 DOI: 10.1371/journal.pone.0062880]
- 80 **Kanaan Z**, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A, Galandiuik S. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. *Ann Surg* 2013; **258**: 400-408 [PMID: 24022433 DOI: 10.1097/SLA.0b013e3182a15bcc]
- 81 **Ahmed FE**, Amed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Allison RR. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. *Cancer Genomics Proteomics* 2012; **9**: 179-192 [PMID: 22798503]
- 82 **Huang Z**, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int J Cancer* 2010; **127**: 118-126 [PMID: 19876917 DOI: 10.1002/ijc.25007]
- 83 **Liu GH**, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, Sun XF. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. *Tumour Biol* 2013; **34**: 2175-2181 [PMID: 23625654 DOI: 10.1007/s13277-013-0753-8]
- 84 **Pu XX**, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Ji-ang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. *J Gastroenterol Hepatol* 2010; **25**: 1674-1680 [PMID: 20880178 DOI: 10.1111/j.1440-1746.2010.06417.x]
- 85 **Wang LG**, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. *Cancer Epidemiol* 2012; **36**: e61-e67 [PMID: 22018950 DOI: 10.1016/j.canep.2011.05.002]
- 86 **Cheng H**, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One* 2011; **6**: e17745 [PMID: 21445232 DOI: 10.1371/journal.pone.0017745]
- 87 **Wang B**, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. *J Cancer Res Clin Oncol* 2012; **138**: 1659-1666 [PMID: 22638884 DOI: 10.1007/s00432-012-1244-9]
- 88 **Faltejiskova P**, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. *Cancer Biomark* 2012; **12**: 199-204 [PMID: 23568010 DOI: 10.3233/CBM-130308]
- 89 **Mardis ER**. A decade's perspective on DNA sequencing technology. *Nature* 2011; **470**: 198-203 [PMID: 21307932 DOI: 10.1038/nature09796]
- 90 Human genome at ten: The sequence explosion. *Nature* 2010; **464**: 670-671 [PMID: 20360711 DOI: 10.1038/464670a]
- 91 **Wetterstrand KA**. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available from: URL: <http://www.genome.gov/sequencingcosts>
- 92 **Peters BA**, Kermani BG, Sparks AB, Alferov O, Hong P, Alexeev A, Jiang Y, Dahl F, Tang YT, Haas J, Robasky K, Zaranek AW, Lee JH, Ball MP, Peterson JE, Perazich H, Yeung G, Liu J, Chen L, Kennemer MI, Pothuraju K, Konvicka K, Tsoupko-Sitnikov M, Pant KP, Ebert JC, Nilsen GB, Baccash J, Halpern AL, Church GM, Drmanac R. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. *Nature* 2012; **487**: 190-195 [PMID: 22785314 DOI: 10.1038/nature11236]
- 93 **Su Z**, Ning B, Fang H, Hong H, Perkins R, Tong W, Shi L. Next-generation sequencing and its applications in molecular diagnostics. *Expert Rev Mol Diagn* 2011; **11**: 333-343 [PMID: 21463242 DOI: 10.1586/erm.11.3]
- 94 **Ozsolak F**, Milos PM. RNA sequencing: advances, challenges and opportunities. *Nat Rev Genet* 2011; **12**: 87-98 [PMID: 21191423 DOI: 10.1038/nrg2934]
- 95 **Mardis ER**. Next-generation DNA sequencing methods. *Annu Rev Genomics Hum Genet* 2008; **9**: 387-402 [PMID: 18576944 DOI: 10.1146/annurev.genom.9.081307.164359]
- 96 **Sinicropi D**, Qu K, Collin F, Crager M, Liu ML, Pelham RJ, Pho M, Dei Rossi A, Jeong J, Scott A, Ambannavar R, Zheng C, Mena R, Esteban J, Stephans J, Morlan J, Baker J. Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. *PLoS One* 2012; **7**: e40092 [PMID: 22808097 DOI: 10.1371/journal.pone.0040092]
- 97 **Lin KT**, Shann YJ, Chau GY, Hsu CN, Huang CY. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing. *Oncogene* 2013; Epub ahead of print [PMID: 24141781 DOI: 10.1038/onc.2013.424]
- 98 **Iacobucci I**, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, Martinelli G. Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. *Blood Cancer J* 2012; **2**: e61 [PMID: 22829256 DOI: 10.1038/bcj.2012.6]
- 99 **Xiao W**, Tran B, Staudt LM, Schmitz R. High-throughput RNA sequencing in B-cell lymphomas. *Methods Mol Biol* 2013; **971**: 295-312 [PMID: 23296971 DOI: 10.1007/978-1-6270-3-269-8\_17]
- 100 **Berger MF**, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. *Genome Res* 2010; **20**: 413-427 [PMID: 20179022 DOI: 10.1101/gr.103697.109]
- 101 **Kunz M**, Dannemann M, Kelso J. High-throughput sequencing of the melanoma genome. *Exp Dermatol* 2013; **22**: 10-17 [PMID: 23174022 DOI: 10.1111/exd.12054]
- 102 **Cheng P**, Cheng Y, Li Y, Zhao Z, Gao H, Li D, Li H, Zhang T. Comparison of the gene expression profiles between smokers with and without lung cancer using RNA-Seq. *Asian Pac J Cancer Prev* 2012; **13**: 3605-3609 [PMID: 23098441]
- 103 **Kalari KR**, Rossell D, Necela BM, Asmann YW, Nair A, Baheti S, Kachergus JM, Younkin CS, Baker T, Carr JM, Tang X, Walsh MP, Chai HS, Sun Z, Hart SN, Leontovich AA, Hossain A, Kocher JP, Perez EA, Reisman DN, Fields AP, Thompson EA. Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. *Front Oncol* 2012; **2**: 12 [PMID: 22655260 DOI: 10.3389/fonc.2012.00012]
- 104 **Wu Y**, Wang X, Wu F, Huang R, Xue F, Liang G, Tao M, Cai P, Huang Y. Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. *PLoS One* 2012; **7**: e41001 [PMID: 22905095 DOI: 10.1371/journal.pone.0041001]
- 105 **Atkinson SR**, Marguerat S, Bähler J. Exploring long non-coding RNAs through sequencing. *Semin Cell Dev Biol* 2012; **23**: 200-205 [PMID: 22202731 DOI: 10.1016/j.semdb.2011.12.003]
- 106 **Guenzl PM**, Barlow DP. Macro lncRNAs: a new layer of cis-

- regulatory information in the mammalian genome. *RNA Biol* 2012; **9**: 731-741 [PMID: 22617879 DOI: 10.4161/rna.19985]
- 107 **Prensner JR**, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov* 2011; **1**: 391-407 [PMID: 22096659 DOI: 10.1158/2159-8290.CD-11-0209]
- 108 **Shi X**, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett* 2013; **339**: 159-166 [PMID: 23791884 DOI: 10.1016/j.canlet.2013.06.013]
- 109 **de Kok JB**, Verhaegh GW, Roelofs RW, Hessels D, Kiemeny LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. *Cancer Res* 2002; **62**: 2695-2698 [PMID: 11980670]
- 110 **Hessels D**, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeny LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. *Eur Urol* 2003; **44**: 8-15; discussion 15-16 [PMID: 12814669]
- 111 **Day JR**, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. *Cancer Lett* 2011; **301**: 1-6 [PMID: 21093148 DOI: 10.1016/j.canlet.2010.10.019]
- 112 **Ge X**, Chen Y, Liao X, Liu D, Li F, Ruan H, Jia W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. *Med Oncol* 2013; **30**: 588 [PMID: 23640607 DOI: 10.1007/s12032-013-0588-6]
- 113 **Zhai H**, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. *Clin Colorectal Cancer* 2013; **12**: 261-266 [PMID: 24012455 DOI: 10.1016/j.clcc.2013.06.003]
- 114 **Ling H**, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Res* 2013; **23**: 1446-1461 [PMID: 23796952 DOI: 10.1101/gr.152942.112]
- 115 **Kogo R**, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. *Cancer Res* 2011; **71**: 6320-6326 [PMID: 21862635 DOI: 10.1158/0008-5472.CAN-11-1021]
- 116 **Lu L**, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. *Breast Cancer Res Treat* 2012; **136**: 875-883 [PMID: 23124417 DOI: 10.1007/s10549-012-2314-z]
- 117 **Xu C**, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. *Int J Oncol* 2011; **39**: 169-175 [PMID: 21503572 DOI: 10.3892/ijo.2011.1007]
- 118 **Leon SA**, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res* 1977; **37**: 646-650 [PMID: 837366]
- 119 **Choi JJ**, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. *Immunology* 2005; **115**: 55-62 [PMID: 15819697 DOI: 10.1111/j.1365-2567.2005.02130.x]
- 120 **Schwarzenbach H**, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer* 2011; **11**: 426-437 [PMID: 21562580 DOI: 10.1038/nrc3066]
- 121 **Kaiser J**. Medicine. Keeping tabs on tumor DNA. *Science* 2010; **327**: 1074 [PMID: 20185705 DOI: 10.1126/science.327.5969.1074]
- 122 **Feinberg AP**, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature* 1983; **301**: 89-92 [PMID: 6185846]
- 123 **Sandoval J**, Esteller M. Cancer epigenomics: beyond genomics. *Curr Opin Genet Dev* 2012; **22**: 50-55 [PMID: 22402447 DOI: 10.1016/j.gde.2012.02.008]
- 124 **Jones PA**, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002; **3**: 415-428 [PMID: 12042769 DOI: 10.1038/nrg816]
- 125 **Gyparakis MT**, Basdra EK, Papavassiliou AG. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. *J Mol Med (Berl)* 2013; **91**: 1249-1256 [PMID: 24057814 DOI: 10.1007/s00109-013-1088-z]
- 126 **Goessl C**, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. *Cancer Res* 2000; **60**: 5941-5945 [PMID: 11085508]
- 127 **Nakayama H**, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. *Int J Cancer* 2003; **105**: 491-493 [PMID: 12712439 DOI: 10.1002/ijc.11117]
- 128 **Lecomte T**, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. *Int J Cancer* 2002; **100**: 542-548 [PMID: 12124803 DOI: 10.1002/ijc.10526]
- 129 **Grady WM**, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. *Cancer Res* 2001; **61**: 900-902 [PMID: 11221878]
- 130 **Leung WK**, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. *Am J Gastroenterol* 2005; **100**: 2274-2279 [PMID: 16181380 DOI: 10.1111/j.1572-0241.2005.50412.x]
- 131 **Esteller M**, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. *Cancer Res* 1999; **59**: 67-70 [PMID: 9892187]
- 132 **Sanchez-Cespedes M**, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. *Cancer Res* 2000; **60**: 892-895 [PMID: 10706101]
- 133 **Domínguez G**, Carballido J, Silva J, Silva JM, García JM, Menéndez J, Provencio M, España P, Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. *Clin Cancer Res* 2002; **8**: 980-985 [PMID: 11948103]
- 134 **Yin H**, Liang Y, Yan Z, Liu B, Su Q. Mutation spectrum in human colorectal cancers and potential functional relevance. *BMC Med Genet* 2013; **14**: 32 [PMID: 23497483 DOI: 10.1186/1471-2350-14-32]
- 135 **Sorenson GD**, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. *Cancer Epidemiol Biomarkers Prev* 1994; **3**: 67-71 [PMID: 8118388]
- 136 **Vasioukhin V**, Anker P, Maurice P, Lyautey J, Lederrey C, Stroum M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. *Br J Haematol* 1994; **86**: 774-779 [PMID: 7918071]

- 137 **Szymańska K**, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, Mendy M, Friesen MD, Whittle H, Montesano R, Hainaut P. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. *Int J Cancer* 2004; **110**: 374-379 [PMID: 15095302 DOI: 10.1002/ijc.20103]
- 138 **Diehl F**, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci USA* 2005; **102**: 16368-16373 [PMID: 16258065 DOI: 10.1073/pnas.0507904102]
- 139 **Diehl F**, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008; **14**: 985-990 [PMID: 18670422 DOI: 10.1038/nm.1789]
- 140 **Gormally E**, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. *Mutat Res* 2007; **635**: 105-117 [PMID: 17257890 DOI: 10.1016/j.mrrev.2006.11.002]
- 141 **Hibi K**, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. *Cancer Res* 1998; **58**: 1405-1407 [PMID: 9537240]
- 142 **Ito S**, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of tumor DNA in serum of colorectal cancer patients. *Jpn J Cancer Res* 2002; **93**: 1266-1269 [PMID: 12460469]
- 143 **Chen XQ**, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. *Nat Med* 1996; **2**: 1033-1035 [PMID: 8782463]
- 144 **Nawroz H**, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. *Nat Med* 1996; **2**: 1035-1037 [PMID: 8782464]
- 145 **He Y**, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. *Nature* 2010; **464**: 610-614 [PMID: 20200521 DOI: 10.1038/nature08802]
- 146 **Kuo SJ**, Chen M, Ma GC, Chen ST, Chang SP, Lin WY, Chen YC, Lee TH, Lin TT, Liu CS. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation. *Cancer Genet Cytogenet* 2010; **201**: 94-101 [PMID: 20682393 DOI: 10.1016/j.cancergencyto.2010.05.013]
- 147 **Hibi K**, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. *Int J Cancer* 2001; **94**: 429-431 [PMID: 11745425]
- 148 **Köhler C**, Radpour R, Berekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. *Mol Cancer* 2009; **8**: 105 [PMID: 19922604 DOI: 10.1186/1476-4598-8-105]
- 149 **Mehra N**, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. *Clin Cancer Res* 2007; **13**: 421-426 [PMID: 17255261 DOI: 10.1158/1078-0432.CCR-06-1087]
- 150 **Zachariah RR**, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. *Obstet Gynecol* 2008; **112**: 843-850 [PMID: 18827127 DOI: 10.1097/AOG.0b013e3181867bc0]
- 151 **Takeuchi H**, Fujimoto A, Hoon DS. Detection of mitochondrial DNA alterations in plasma of malignant melanoma patients. *Ann N Y Acad Sci* 2004; **1022**: 50-54 [PMID: 15251939 DOI: 10.1196/annals.1318.009]
- 152 **Okochi O**, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T, Nakao A. Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. *Clin Cancer Res* 2002; **8**: 2875-2878 [PMID: 12231530]
- 153 **Polyak K**, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat Genet* 1998; **20**: 291-293 [PMID: 9806551 DOI: 10.1038/3108]
- 154 **Schaaij-Visser TB**, de Wit M, Lam SW, Jiménez CR. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. *Biochim Biophys Acta* 2013; **1834**: 2242-2258 [PMID: 23376433 DOI: 10.1016/j.bbapap.2013.01.029]
- 155 **Lleonart ME**, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, Mendy M, Hollstein MC, Montesano R, Groopman JD, Hainaut P, Friesen MD. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 2956-2962 [PMID: 16365016 DOI: 10.1158/1055-9965.EPI-05-0612]
- 156 **Taguchi A**, Hanash SM. Unleashing the power of proteomics to develop blood-based cancer markers. *Clin Chem* 2013; **59**: 119-126 [PMID: 23099557 DOI: 10.1373/clinchem.2012.184572]
- 157 **Engwegen JY**, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. *World J Gastroenterol* 2006; **12**: 1536-1544 [PMID: 16570345]
- 158 **Ostroff RM**, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. *PLoS One* 2010; **5**: e15003 [PMID: 21170350 DOI: 10.1371/journal.pone.0015003]
- 159 **de Wit M**, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. *Clin Biochem* 2013; **46**: 466-479 [PMID: 23159294 DOI: 10.1016/j.clinbiochem.2012.10.039]
- 160 **Kanaan Z**, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. *Ann Surg* 2012; **256**: 544-551 [PMID: 22868372 DOI: 10.1097/SLA.0b013e318265bd6f]
- 161 **Toiyama Y**, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. *J Natl Cancer Inst* 2013; **105**: 849-859 [PMID: 23704278 DOI: 10.1093/jnci/djt101]
- 162 **Menéndez P**, Padilla D, Villarejo P, Palomino T, Nieto P, Menéndez JM, Rodríguez-Montes JA. Prognostic implications of serum microRNA-21 in colorectal cancer. *J Surg Oncol* 2013; **108**: 369-373 [PMID: 23970420 DOI: 10.1002/jso.23415]
- 163 **Huang Y**, Yang YB, Zhang XH, Yu XL, Wang ZB, Cheng XC. MicroRNA-21 gene and cancer. *Med Oncol* 2013; **30**: 376 [PMID: 23277281 DOI: 10.1007/s12032-012-0376-8]
- 164 **Baraniskin A**, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnoij A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. *Int J Cancer* 2013; **132**: E48-E57 [PMID: 22907602 DOI: 10.1002/ijc.27791]
- 165 **Zauber AG**, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for

colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2008; **149**: 659-669 [PMID: 18838717]

166 **Rockey DC**, Paulson E, Niedzwiecki D, Davis W, Bosworth HB, Sanders L, Yee J, Henderson J, Hatten P, Burdick S, Sanyal A, Rubin DT, Sterling M, Akerkar G, Bhutani MS,

Binmoeller K, Garvie J, Bini EJ, McQuaid K, Foster WL, Thompson WM, Dachman A, Halvorsen R. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet* 2005; **365**: 305-311 [PMID: 15664225 DOI: 10.1016/S0140-6736(05)17784-8]

**P- Reviewers:** Nishiyama M, Stanojevic GZ **S- Editor:** Zhai HH

**L- Editor:** A **E- Editor:** Liu SQ



## Colorectal carcinoma in a Southern Mediterranean country: The Libyan scenario

Zuhir Bodalal, Riyad Bendardaf

Zuhir Bodalal, Department of Medicine, Faculty of Medicine, Libyan International Medical University, Benghazi, Libya  
Riyad Bendardaf, Department of Medicine, Oncology Unit, University Hospital Sharjah, Sharjah, United Arab Emirates  
Author contributions: Bodalal Z and Bendardaf R conceived the idea of the project; Bodalal Z gathered the data and performed the statistical analysis; Bodalal Z and Bendardaf R performed the literature review; Bodalal Z wrote the manuscript.

Correspondence to: Dr. Zuhir Bodalal, Department of Medicine, Faculty of Medicine, Libyan International Medical University, P.O. Box 15016, Benghazi, Libya. [zuhir.bodalal@limu.edu.ly](mailto:zuhir.bodalal@limu.edu.ly)  
Telephone: +218-91-4789141 Fax: +218-61-2233909  
Received: September 12, 2013 Revised: December 26, 2013  
Accepted: February 16, 2014  
Published online: April 15, 2014

### Abstract

**AIM:** To study the salient features of colorectal cancer (CRC) in Libya.

**METHODS:** Patients records were gathered at the primary oncology clinic in eastern Libya for the period of one calendar year (2012). Using this data, various parameters were analyzed and age-standardized incidence rates were determined using the direct method and the standard population.

**RESULTS:** During 2012, 174 patients were diagnosed with CRC, 51.7% ( $n = 90$ ) male and 48.3% ( $n = 84$ ) females. The average age was 58.7 ( $\pm 13.4$ ) years, with men around 57.3 ( $\pm 13$ ) years old and women usually 60.1 ( $\pm 13.8$ ) years of age. Libya has the highest rate of CRC in North Africa, with an incidence closer to the European figures. The age-standardized rate for CRC was 17.5 and 17.2/100000 for males and females respectively. It was the second most common cancer, forming 19% of malignancies, with fluctuation in ranking and incidence in different cities/villages. Increasingly, younger ages are being afflicted and a higher proportion of patients are among the > 40 years subset.

Nearly two-thirds presented at either stage III (22.4%) or IV (38.4%).

**CONCLUSION:** Cancer surveillance systems should be established in order to effectively monitor the situation. Likewise, screening programs are invaluable in the Libyan scenario given the predominance of sporadic cases.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Colorectal carcinoma; Cancer incidence; Age-standardized rates; Benghazi, Libya; North Africa; Young age; Urban-rural differences

**Core tip:** Colorectal cancer incidence in Libya has changed greatly since the last time it was determined nearly a decade ago. Libya was found to have the highest incidence rate in North Africa, with younger ages more affected. Late presentation was found to be a major problem in the Libyan case. Clear urban-rural differences were seen when the different districts were analyzed. Different hypotheses are put forth to explain these variations. Proper surveillance and screening programs need to be established and healthcare policies should be adjusted to take into account the increasing rate of this malignancy.

Bodalal Z, Bendardaf R. Colorectal carcinoma in a Southern Mediterranean country: The Libyan scenario. *World J Gastrointest Oncol* 2014; 6(4): 98-103 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v6/i4/98.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v6.i4.98>

### INTRODUCTION

Colorectal cancer (CRC) is one of the most common

malignant tumors worldwide<sup>[1,2]</sup>, with the disease incidence rising with advanced age<sup>[3,4]</sup>. The overall mortality from CRC is 60%, which represents the second leading cause of cancer death in western societies. Figures on incidence from Libyan sources are over a decade old and have multiple limitations<sup>[5]</sup>. Unfortunately, there has not been a major improvement in patient survival despite the advances made in our understanding of disease and in chemotherapy practice<sup>[6]</sup>. Surgical cure of CRC is determined by stage of the tumor and its biological behavior. Early CRCs can be cured with surgery alone.

Even today, most CRC patients undergo potentially curative surgery and receive adjuvant chemotherapy but approximately 50% of the patients initially thought to be cured subsequently relapse and die of their disease<sup>[7]</sup>. Advanced CRC is defined as a disease that is either metastatic or locally advanced and in which surgical resection is unlikely to be curative<sup>[8]</sup>. Once metastasis has occurred, the patient's prognosis is considerably worse, with the 5-year survival rate being < 5%<sup>[8]</sup>. For the majority of patients, chemotherapy can yield improvements in survival and is the main modality of treatment in these patients<sup>[9]</sup>.

CRC was found to be the leading malignancy in Libyan males and the second most prevalent among females<sup>[10]</sup>. On a global scale, it is the third most common form of cancer<sup>[11]</sup>.

On the whole, the incidence of colorectal carcinoma in Middle Eastern countries is lower than that of Western countries<sup>[12]</sup>. The North African countries have consistently contributed their registry data to scientific literature<sup>[13-18]</sup>. Due to a number of difficulties, very limited data exists for Libya<sup>[10,19,20]</sup>. Moreover, epidemiological features of CRC have never been studied, despite being a major form of malignancy. A unique research opportunity is offered in the Libyan scenario where the traditional lifestyle still prevails in rural areas and the urban (Westernized) mode of living dominates in the cities.

Using data that was actively collected from the Department of Oncology at the Benghazi Medical Center, the primary oncology center in eastern Libya, the salient features of colorectal carcinoma patients were analyzed.

## MATERIALS AND METHODS

### Study population

Libya is a North African country categorized under the Eastern Mediterranean Regional Office in the WHO classification. According to the 2006 census, over 5.5 million people lived in Libya, with 28.5% ( $n = 1613749$ ) residing in the eastern part of the country. Benghazi is the largest city in eastern Libya, with over 670000 inhabitants. The catchment area includes eight major locations comprising urban, suburban and rural populations (Figure 1) and patients were classified under these main districts according to proximity.

### Ethical approval

The study was approved by the Biomedical Ethics Committee at the Libyan International Medical University. All



**Figure 1** Map of Libya highlighting the districts that were studied and included in the eastern Libya cancer pool.

personal identifiers were stripped from the data and only medically significant data was analyzed.

### Data collection

Data was obtained from the patient records at the Department of Oncology in the Benghazi Medical Center who were diagnosed from the period of January 1<sup>st</sup> to December 31<sup>st</sup>, 2012. In Libya, an ineffective primary health system forces the populace to deal directly with outpatient departments in secondary and tertiary centers. This is true for Libyan oncology patients where they all present to the oncological outpatient department after a referral from another specialty. They are then diagnosed and given a treatment plan. The department effectively receives all the cancer cases in Benghazi and the overwhelming majority of the cases in eastern Libya (being the only oncological center in the region). The patients were diagnosed through various techniques, particularly microscopic verification and clinically/radiologically diagnosis. However, due to clerical difficulties, this parameter (*i.e.*, the method of diagnosis) could not reliably be collected for all patients and hence was excluded from the analysis. This data serves as a good indicator for eastern Libya in general and Benghazi in particular.

Hematological malignancies were not included in this study since such patients are recorded at the Department of Hematology and their data was not made available.

Different parameters were recorded for each patient: age, gender, city, type of cancer, subtype and staging. In the light of clerical errors, a number of cases were set aside for a certain parameter but used for others. The patients were filtered by city of origin to include only patients residing in the eastern part and not referrals.

### Statistical analysis

The data was computerized in a data sheet and organized as per International Classification of Diseases for Oncol-




Figure 2 Population pyramid of the colorectal cancer patients split by gender.

ogy (ICD-O). An SPSS-based model was designed that spanned the collected data and basic statistical procedures were performed (*t* tests and  $\chi^2$  tests).

The 2012 Libyan population was determined using the 2006 Libyan census, taking into consideration the appropriate population growth. Age-specific incidence and age-standardized rates (ASRs) were calculated *via* the direct method using the standard population distribution<sup>[15]</sup> arranged by site (ICD-O).

## RESULTS

During 2012, a total of 174 patients were diagnosed with colorectal carcinoma in the eastern region of Libya. Slightly over half of the cases (51.7%, *n* = 90) were male, while 48.3% (*n* = 84) were females. The average overall age of the patients was 58.7 ( $\pm$  13.4) years, with men around 57.3 ( $\pm$  13) years old and women usually 60.1 ( $\pm$  13.8) years of age. The ASR for CRC was 17.5 and 17.2/100000 for males and females respectively. It was the second most common cancer overall in the eastern region, forming 19% of all malignancies, with fluctuation in ranking in different towns/villages.

When the age was categorized into groups, it was found that a peak occurred in the 60-64 year age group (17.1%, *n* = 29), which was true for both genders. Nearly one tenth of colorectal carcinoma patients (9.4%, *n* = 16) were diagnosed < 40 years. Males were more than two-thirds (68.8%, *n* = 11) of these patients, giving a male to female ratio of 2.2. One quarter of CRC patients (23.5%, *n* = 40) presented before the age of 50 years and that figure jumped to over one-third of patients when cases under 55 years are studied (35.3%, *n* = 60). Figure 2 depicts the distribution of CRC by age and gender.

The three areas that contributed the greatest number of colon cancer cases were Benghazi (64.9%, *n* = 113), Al-Beida (9.8%, *n* = 17) and Al-Marj (8%, *n* = 14). When looking at population distribution from the Libyan 2006




Figure 3 Distribution of colorectal cancer patients according to clinical stage at diagnosis.

Table 1 Display of key parameters of the cancer patients in eastern Libya

	Overall		Male		Female	
Age (n/SD)	58.7	13.4	57.3	13.0	60.1	13.8
Age group (n/%)						
20-29 yr	6	3.5	4	4.7	2	2.4
30-39 yr	10	5.9	7	8.1	3	3.6
40-49 yr	24	14.1	10	11.6	14	16.6
50-59 yr	42	24.7	20	23.3	22	26.2
60-69 yr	54	31.8	32	37.2	22	26.2
70-79 yr	26	15.3	12	14.0	14	16.6
80+ yr	8	4.7	1	1.1	7	8.4
Total	170	100.0	86	100.0	84	100.0
Nationality (n/%)						
Libyan	170	98.3	89	100.0	81	96.4
Non-Libyan	3	1.7	0	0.0	3	3.6
Total	173	100.0	89	100.0	84	100.0
City of origin (n/%)						
Ajdabia	8	4.6	6	6.7	2	2.4
Beida	17	9.8	9	10.0	8	9.5
Benghazi	113	64.9	56	62.2	57	67.9
Derna	6	3.4	3	3.3	3	3.6
Kufra	4	2.3	0	0.0	4	4.8
Marj	14	8.0	8	8.9	6	7.1
Tobruk	12	6.9	8	8.9	4	4.8
Total	174	100.0	90	100.0	84	100.0

census, one clearly observes that the city of Benghazi is over-represented, while the other (more rural) areas were starkly under-represented. Nearly two-thirds of colon cancer patients were from Benghazi, whereas its inhabitants constitute only 41% of the population in eastern Libya ( $\chi^2 = 41.291$ , *P* < 0.001). A small proportion (1.7%, *n* = 3) of the colon cancer patients were foreign nationals. The detailed classification and distribution of these parameters can be seen in Table 1.

The clinical stage was recorded for 125 patients (71.8%) and 49 were excluded due to clerical errors. The majority of cases (38.4%, *n* = 48) presented at stage IV with another 28 patients at stage III (22.4%). This is further highlighted in Figure 3.

The cases were classified on the site of the cancer as being either right-sided or left-sided colorectal carcinoma. Cancers of the left colon were more common (78.6%,

**Table 2** Distribution of the cases in terms of clinical staging, site of cancer and histopathological grade

	Overall		Male		Female	
Clinical stage (n/%)						
I -A	3	2.4	1	1.5	2	3.4
I -B	7	5.6	5	7.6	2	3.4
II -A	28	22.4	12	18.2	16	27.1
II -B	11	8.8	6	9.1	5	8.5
III -A	5	4.0	4	6.1	1	1.7
III -B	11	8.8	5	7.6	6	10.2
III -C	12	9.6	7	10.6	5	8.5
IV	48	38.4	26	39.4	22	37.3
Total	125	100.0	66	100.0	59	100.0
Site of cancer (n/%)						
Right side	30	21.4	14	18.9	16	24.2
Left side	110	78.6	60	81.1	50	75.8
Total	140	100.0	74	100.0	66	100.0
Histopathological grade (n/%)						
Well differentiated	29	33.3	17	35.4	12	30.8
Moderately differentiated	47	54.0	27	56.3	20	51.3
Poorly differentiated	11	12.6	4	8.3	7	17.9
Total	87	100.0	48	100.0	39	100.0

**Table 3** The distribution of colorectal carcinoma based on site

Specific site	n	%
Anus	1	0.7
Appendix	1	0.7
Asc. colon	4	2.8
Cecum	6	4.2
Left side	25	17.5
Rectum	52	36.4
Right side	19	13.3
Sigmoid	35	24.5
Total	143	100.0

**Table 4** Comparison of colorectal cancer incidence rates (age-adjusted per 10<sup>5</sup>)

Country	Male	Female
Benghazi, Libya (2012) <sup>[11]</sup>	17.5	17.2
Benghazi, Libya (2003) <sup>[10]</sup>	11.6	8.8
Western Libya <sup>[11]</sup>	14.2	12.0
Algeria (Setif, 1998-2002) <sup>[6]</sup>	6.6	6.8
Algeria (Alger, 2006) <sup>[7]</sup>	14.8	11.0
Egypt (Gharbiah, 1999-2002) <sup>[6]</sup>	6.3	4.4
Tunisia (Sousse, 1998-2002) <sup>[6]</sup>	11.6	9.0
Tunisia (Sfax, 2000-2002) <sup>[9]</sup>	11.5	9.1
Morocco (Rabat, 2005) <sup>[4]</sup>	7.2	4.6
Morocco (Casablanca, 2004) <sup>[5]</sup>	6.6	5.7
European Pool (MECC)	22.0	15.6
Iran <sup>[15]</sup>	8.2	7.0

$n = 110$ ) than their right-sided counterparts (21.4%,  $n = 30$ ). This is shown with other parameters in Table 2. When the specific sites were studied (*i.e.*, sigmoid, rectal, *etc.*), we found that rectal carcinomas were the most common form (36.4%,  $n = 52$ ). This can be seen in Table 3.

Histopathologically, 87 patients (50%) had graded carcinomas. Most were moderately differentiated (54%,  $n = 47$ ), followed by well differentiated (33.3%,  $n = 29$ )

carcinomas; poorly differentiated cancers were the least common (12.6%,  $n = 11$ ). This is further described in Table 2.

## DISCUSSION

In terms of incidence, the average rate for Middle Eastern countries was reported as 3/100000-7/100000<sup>[21,22]</sup>. Even among the North African countries, eastern Libya claims the highest ASR for colon cancer (Table 4)<sup>[10,19,23]</sup>. While the exact reasons for this inordinately high rate remain to be ascertained, genetic predisposition, increased Westernization of the Libyan diet, physical inactivity and lack of screening programs may be considered important predisposing factors.

The distribution of colon cancer cases was fairly equal between the genders, despite a conflict in previous literature between reports supporting and others negating a difference between men and women. In terms of age, there was no significant difference between the genders ( $P = 0.072$ ). The male to female ratio, skewed towards males in the < 40 years subset, was much higher than other nations<sup>[24]</sup>.

Similarly to neighboring Egypt, younger age groups are affected with CRC<sup>[25]</sup>. One of the principle hypotheses for this trend is that the younger generation live a more Westernized lifestyle (*i.e.*, unhealthy diet with low exercise) and are hence at greater risk<sup>[26]</sup>. This is of particular importance since the prognosis proportionately worsens below the age of 40 years<sup>[27]</sup>.

Benghazi is the largest city in eastern Libya and the second largest in all of Libya, with a population approaching 800000 inhabitants. Colon cancer was more common in the urban environment in Libya, potentially due to a more sedentary lifestyle, more Westernized diet and a subsequently higher prevalence of obesity. The rural areas in Libya have maintained a relatively traditional way of life with farming, animal rearing and small industries as the main occupations. Traditional cuisine focusing on whole grain and Mediterranean style meals is more common in that environment. While the urban-rural difference has been proven for breast cancer<sup>[28]</sup>, the literature for colon cancer is scanty globally and virtually non-existent for the region.

Foreign nationals are less likely to present to the oncology clinic in Libya as they are more apt to return to their home countries and seek their family upon receiving such news. This would explain their small proportion in the sample.

Over 60% of patients presented at the oncology clinic at advanced stages (III/IV) when the long term prognosis is grim. Around 22.4% ( $n = 28$ ) of our patients were diagnosed at stage III, while 38.4% ( $n = 48$ ) presented at stage IV. This was found to be similar for other major forms of cancer studied in Libya<sup>[10]</sup>. The major problem in the Libyan scenario is late presentation. This could be due a number of different reasons, among them awareness and social stigma. Transport difficulties in rural areas

as well as the distance to Benghazi also serve as a hindrance to early detection.

Screening programs would greatly increase the catchment rate of our CRC patients before they reach these late stages. This is especially important in the sporadic cases, which form the majority of cases.

The Libyan diet is traditional in certain areas and modern (Westernized) in others. This is a reflection of the rural-urban differences that exist. With the increase of consumption of Western-style cooking and the downwards trend of traditional food, it is expected that there would be a rise in the incidence of CRC. However, a long term study is required in order to determine such a trend. Further risk factors also exist in Libyan society, such as a high rate of diabetes mellitus, smoking, obesity, *etc.*

Certain limitations, however, need to be mentioned, namely the quality of the patient records. In the gathering of this data, not all the parameters were available for all the patients and hence they were excluded from the analysis. The data that was gathered for this study was from one center and, even although it is the sole oncological center in the region, there will surely be a certain number of missed cases or patients who immediately sought care abroad without referral to our center first. Additionally, while this data is representative of eastern Libya, we cannot generalize this for all of Libya. In cancer epidemiology, stark differences may exist between different regions of a country.

In conclusion, Libya has a higher rate of CRC than neighboring countries, with an incidence that is closer to the European figures. Increasingly, younger ages are being afflicted and a higher proportion of patients are among the > 40 years subset. Urban-rural differences were observed in the Libyan scenario. A major problem is delayed presentation with a large proportion of patients seeking medical care at advanced or late stages with a poor prognosis. Screening programs are sorely needed in Libya in order to combat presentation at late stages.

## COMMENTS

### Background

Cancer epidemiology is a rapidly growing field that has made great strides in the last few decades; however, it has always been developed countries that have contributed the majority of data and figures. As a consequence, most of the information available on cancer incidence is based on those societies. In the developing world, this information is extracted with more difficulty. This is especially true in Libya where data gathering is notoriously difficult (for a myriad of reasons). For the first time, colorectal cancer (CRC) patients in Libya were studied and the findings were presented.

### Research frontiers

There is now a focus on customization of epidemiology for different countries and even different regions within a single country. Preventive medicine has taken the lead in epidemiology and a baseline needs to be determined before any cancer plan can be established at a national or local level.

### Innovations and breakthroughs

Colon cancer was found to be the leading malignancy in Libyan males and the second most prevalent among females. Despite that, there has never been a study on CRC in Libya. Using population data from the 2006 Libyan census with projections for future years, the age-standardized rates (ASR) was calculated. Various parameters were gathered for the patients, among them, age, national-

ity, affected site within the colon, histopathological grade and the clinical stage. The geographical distribution of CRC patients in Libya was also studied for the first time.

### Applications

Using the findings from this study, the health authorities in Libya can finally lay a plan to help combat CRC. A major problem in the Libyan scenario is late presentation, so increased awareness among the populace and a higher index of suspicion among clinicians would surely save countless lives. Certain regions contributed more in terms of patient load and hence more focus needs to be placed there.

### Terminology

ASR: ASR is an internationally used measure of new cancer cases relative to the standard world population (as stated in the Cancer in Five Continents series).

### Peer review

It is a descriptive study that intended to demonstrate the effect of changing food habits in Libyan people. This is an interesting article.

## REFERENCES


- 1 **Gatta G**, Faivre J, Capocaccia R, Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. EURO-CARE Working Group. *Eur J Cancer* 1998; **34**: 2176-2183 [PMID: 10070284 DOI: 10.1016/S0959-8049(98)00327-X]
- 2 **Repetto L**, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W, Pietropaolo M. Geriatric oncology: a clinical approach to the older patient with cancer. *Eur J Cancer* 2003; **39**: 870-880 [PMID: 12706355 DOI: 10.1016/S0959-8049(03)00062-5]
- 3 **Wymenga AN**, Slaets JP, Sleijfer DT. Treatment of cancer in old age, shortcomings and challenges. *Neth J Med* 2001; **59**: 259-266 [PMID: 11705645 DOI: 10.1016/S0300-2977(01)00160-7]
- 4 **Franceschi S**, La Vecchia C. Cancer epidemiology in the elderly. *Crit Rev OncolHematol* 2001; **39**: 219-226 [PMID: 11500263 DOI: 10.1016/S1040-8428(01)00102-0]
- 5 **El Mistiri M**, Pirani M, El Sahli N, El Mangoush M, Attia A, Shembesh R, Habel S, El Homry F, Hamad S, Federico M. Cancer profile in Eastern Libya: incidence and mortality in the year 2004. *Ann Oncol* 2010; **21**: 1924-1926 [PMID: 20624785 DOI: 10.1093/annonc/mdq334]
- 6 **Walker J**, Quirke P. Biology and genetics of colorectal cancer. *Eur J Cancer* 2001; **37** Suppl 7: S163-S172 [PMID: 11887987 DOI: 10.1016/S0959-8049(01)80018-6]
- 7 **Staib L**, Link KH, Blatz A, Beger HG. Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients--monoinstitutional experience. *World J Surg* 2002; **26**: 59-66 [PMID: 11898035 DOI: 10.1007/s00268-001-0182-5]
- 8 **Young A**, Rea D. ABC of colorectal cancer: treatment of advanced disease. *BMJ* 2000; **321**: 1278-1281 [PMID: 11082094 DOI: 10.1136/bmj.321.7271.1278]
- 9 **Christopoulou A**. Chemotherapy in metastatic colorectal cancer. *Tech Coloproctol* 2004; **8** Suppl 1: s43-s46 [PMID: 15655639 DOI: 10.1007/s10151-004-0108-7]
- 10 **Bodalal Z**, Azzuz R, Bendardaf R. Cancer in Eastern Libya: Results from Benghazi Medical Center. *World J Gastroenterol* 2014; in press
- 11 **Parkin DM**. Global cancer statistics in the year 2000. *Lancet Oncol* 2001; **2**: 533-543 [PMID: 11905707 DOI: 10.1016/S1470-2045(01)00486-7]
- 12 **Salim EI**, Moore MA, Al-Lawati JA, Al-Sayyad J, Bazawir A, Bener A, Corbex M, El-Saghir N, Habib OS, Maziak W, Mokhtar HC, Seif-Eldrin IA, Sobue T. Cancer epidemiology and control in the arab world - past, present and future. *Asian Pac J Cancer Prev* 2009; **10**: 3-16 [PMID: 19469617]
- 13 **Tazi M**, Benjaafar N, Er-Raki A. Incidence des Cancers a Rabat-Annee 2005. *Registre des Cancers de Rabat* 2009. Ac-

- cessible from: URL: [http://www.fmp-usmba.ac.ma/pdf/Documents/cancer\\_registry\\_mor\\_rabat.pdf](http://www.fmp-usmba.ac.ma/pdf/Documents/cancer_registry_mor_rabat.pdf)
- 14 **Benider A**, Bennani M, Harif M. Registre des Cancers de la Region du grand Casablanca, Annee 2004. Registre des Cancers du grand Casablanca, 2007. Accessible from: URL: [http://www.contrelecancer.ma/site\\_media/uploaded\\_files/Registre\\_des\\_Cancers\\_de\\_la\\_Re%C3%BCgion\\_du\\_grand\\_Casablanca\\_2004.pdf](http://www.contrelecancer.ma/site_media/uploaded_files/Registre_des_Cancers_de_la_Re%C3%BCgion_du_grand_Casablanca_2004.pdf)
  - 15 **Curado M**, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer Incidence in Five Continents. Lyon: IARC Scientific Publications, 2008
  - 16 Registre des Tumeurs d'Alger Annee 2006. Ministere del la Sante et de la Population: Institut National de Sante Publique, 2007. Accessible from: URL: <http://www.sante.dz/insp/registre-tumeurs-alger-2006.pdf>
  - 17 **Ben Abdallah M**, Zehani S, Hizem Ben Ayoub W. North Tunisia Cancer Registry. Third report: 1999-2003. Internal report. 2006
  - 18 **Sellami A**, Sellami Boudawara T. Incidence des cancers dans le Gouvernorat de Sfax 2000-2002. Institut National de la Santé Publique, 2007. Accessible from: URL: [http://www.emro.who.int/images/stories/tunisia/documents/incidence\\_des\\_cancers\\_dans\\_le\\_gouvernorat\\_de\\_sfax\\_2000-2002\\_Ahmed\\_SellamiMohamed\\_Hsairi.pdf](http://www.emro.who.int/images/stories/tunisia/documents/incidence_des_cancers_dans_le_gouvernorat_de_sfax_2000-2002_Ahmed_SellamiMohamed_Hsairi.pdf)
  - 19 **El Mistiri M**, Verdecchia A, Rashid I, El Sahli N, El Mangush M, Federico M. Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003. *Int J Cancer* 2007; **120**: 392-397 [PMID: 17066425 DOI: 10.1002/ijc.22273]
  - 20 **National Oncology Institute**. First Annual Report: Population Based Cancer Registry. Sibratha: Sibratha Cancer Registry, 2008. Accessible from: URL: <http://www.ncisabratha.ly/nci/filesystem/uploads/REPORT1.pdf>
  - 21 **Parkin D**, Whelan S, Ferlay J, Teppo L, Thomas D. Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer, 2002: 715-718 [accessible through IARC website: [www.iarc.fr](http://www.iarc.fr)]
  - 22 **Stewart B**, Kleihues P. World Cancer Report 2003. Lyon: International Agency for Research on Cancer, 2003
  - 23 **Zanetti R**, Tazi MA, Rosso S. New data tells us more about cancer incidence in North Africa. *Eur J Cancer* 2010; **46**: 462-466 [PMID: 20031391 DOI: 10.1016/j.ejca.2009.11.012]
  - 24 **Ansari R**, Mahdavinia M, Sadjadi A, Nouraie M, Kaman-gar F, Bishehsari F, Fakheri H, Semnani S, Arshi S, Zahedi MJ, Darvish-Moghadam S, Mansour-Ghanaei F, Mosavi A, Malekzadeh R. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. *Cancer Lett* 2006; **240**: 143-147 [PMID: 16288832 DOI: 10.1016/j.canlet.2005.09.004]
  - 25 **Gado A**, Ebeid B, Abdelmohsen A, Axon A. Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? *Alex J Med* 2013 [DOI: 10.1016/j.ajme.2013.03.003]
  - 26 **Veruttipong D**, Soliman AS, Gilbert SF, Blachley TS, Hablas A, Ramadan M, Rozek LS, Seifeldin IA. Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. *World J Gastroenterol* 2012; **18**: 3997-4003 [PMID: 22912550 DOI: 10.3748/wjg.v18.i30.3997]
  - 27 **Pal M**. Proportionate increase in incidence of colorectal cancer at an age below 40 years: an observation. *J Cancer Res Ther* 2006; **2**: 97-99 [PMID: 17998686 DOI: 10.4103/0973-1482.27583]
  - 28 **Dey S**, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD. Urban-rural differences in breast cancer incidence in Egypt (1999-2006). *Breast* 2010; **19**: 417-423 [PMID: 20452771 DOI: 10.1016/j.breast.2010.04.005]

**P- Reviewers:** Lin JH, Parsak C, Seetharaman H

**S- Editor:** Song XX **L- Editor:** Roemmele A **E- Editor:** Liu SQ





## GENERAL INFORMATION

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

### Aim and scope

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

*WJGO* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

### Columns

The columns in the issues of *WJGO* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the fore-

front of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in gastrointestinal oncology; (12) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal oncology; (13) Meta-Analysis: Covers the systematic review, mixed-treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJGO*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of gastrointestinal oncology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

### Name of journal

*World Journal of Gastrointestinal Oncology*

### ISSN

ISSN 1948-5204 (online)

## Instructions to authors

### Launch date

October 15, 2009

### Frequency

Monthly

### Editorial-in-Chief

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Kitirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

### Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

*World Journal of Gastrointestinal Oncology*

Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,

Wanchai, Hong Kong, China

Telephone: +852-65557188

Fax: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Telephone: +1-925-2238242

Fax: +1-925-2238243

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm).

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an ex-

pert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book

Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

#### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

#### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

#### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

#### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

#### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

#### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_list.htm](http://www.wjgnet.com/1948-5204/g_info_list.htm).

#### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part

## Instructions to authors

should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial let-

ter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.s]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/0000-3086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computa-

tional effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

#### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

#### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312183048.htm](http://www.wjgnet.com/1948-5204/g_info_20100312183048.htm).

#### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

#### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

#### Examples for paper writing

All types of articles' writing style and requirement will be found in the

link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

## RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

#### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

#### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182928.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182928.htm).

#### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182841.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182841.htm).

#### Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

## STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

## PUBLICATION FEE

*WJGO* is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 698 USD per article. All invited articles are published free of charge.



百世登

**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

